NewzIntel.com

Category: Americas

  • MIL-OSI: Mainspring Expands Channel Network with Leading Resellers as Linear Generator Installations Grow

    Source: GlobeNewswire (MIL-OSI)

    MENLO PARK, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) — Mainspring Energy today announced the expansion of its channel sales network into new markets and geographies, accelerating adoption of the company’s Linear Generators with the addition of three new resellers. The program welcomes dGEN Energy Partners, Gould Group, and INF Associates to the team of partner companies bringing Mainspring’s advanced power generation solutions to commercial and industrial companies.

    The addition of these leading power resellers expands Mainspring’s reach into more projects and vertical markets such as hotels and commercial buildings, EV charging infrastructure, cold storage facilities, and other industrial operations. It also opens the door to delivering projects in new regions for the company, particularly in Puerto Rico and the Caribbean, which are prone to extreme weather events and extended power disruptions. As in the fast-growing U.S. linear generator market, commercial and industrial companies in this region are exploring linear generator solutions for greater control over their energy resources and costs. Mainspring’s products provide resilient, low-emission, rapidly installed power capacity with market-leading flexibility in siting, project scope, load profiles, and fuel types.

    “In an era of unprecedented load growth, demand is spiking globally for reliable, efficient power,” said Wissam Balshe, Senior Director of Channel Partnerships at Mainspring. “dGen, Gould Group and INF bring valuable expertise to our reseller team in deploying advanced power infrastructure in commercial and industrial markets. Together we are expanding our reach and accelerating the transition to cleaner, more efficient power.”

    The expanded reseller network puts Mainspring solutions in the hands of a growing force of industry experts specializing in reliable, affordable, and sustainable power projects that deliver new power capacity. It builds on the launch of the Mainspring reseller network last year and Mainspring’s strategic partnerships with global power leaders Schneider Electric and ABM.

    dGen
    dGen brings a wealth of experience in the renewable energy industry with over 750 MW of clean energy installed today. They are known in the solar industry for their ability to take a project from design to financing to installation with a dedicated team of developers and EPC installers. dGen expands access to renewable energy solutions to all 50 states, Puerto Rico and the Caribbean.

    Gould Group
    As a trusted real estate portfolio fiduciary, Gould Group uses energy efficiency as a strategic tool to enhance cost-effectiveness and quality across industrial, office, hospital, and multifamily properties nationwide. Gould Group stands by three certainties—Budget, Execution, and Quality—ensuring every project is completed on time, within budget, and to the highest standards. Its expertise spans energy procurement, strategic financing, and tailored sustainability solutions, enabling it to maximize efficiency, reduce costs, and create long-term value for its clients.

    INF Associates
    INF is a turnkey energy solutions firm performing complete design, equipment supply, and installation of projects, including electric vehicle (EV) charging solutions, LED lighting upgrades, distributed and renewable energy technologies, and mechanical system retrofits. INF has offices in New York City, the Hudson Valley and New Jersey, and supports energy projects nationwide. INF has a team dedicated to securing funding from utility and state commissions to advance the sustainability goals for each company they work with. Since 2011, INF has secured tens of millions of dollars of utility incentives for energy projects and has installed more than 5,000 EV chargers totaling over 50 megawatts of charging power.

    About Mainspring
    Mainspring Energy manufactures and delivers innovative, flexible, low-emissions onsite power solutions that rapidly add new power capacity and deliver reliable, affordable, clean electric power. The Mainspring Linear Generator is fully dispatchable and scalable from 250 kW to 100+MW. It is uniquely fuel-flexible, operating on any gaseous fuel including hydrogen, ammonia, biogas, natural gas, propane, and others. The company began commercial shipments in 2020 and to date has tens of MWs of power in operation and more than 100 MW in advanced development for leading Fortune 500 companies and utilities. Learn more at mainspringenergy.com.

    Media Contact:

    Marjorie Bonga
    marjorie@teamsilverline.com
    15407462385

    The MIL Network –

  • MIL-OSI Global: Camp Hill virus explained: what are the risks of a henipavirus outbreak in America?

    Source: The Conversation – UK – By Shirin Ashraf, Postdoctoral Researcher, MRC-Centre for Virus Research, University of Glasgow

    A new pathogen, called Camp Hill virus, was recently discovered in Alabama, drawing attention to a group of viruses known as henipaviruses. This is a big deal because other viruses in this group are linked to serious, often fatal, disease, and this is the first time one of them has been found in North America.

    Camp Hill virus was discovered by looking at tissue samples from short-tailed shrews that were collected in 2021. It’s a new species of virus that’s related to other dangerous viruses such as Nipah and Hendra, which have caused serious outbreaks in other parts of the world. It’s also distantly related to the measles virus.

    The first known henipavirus, Hendra virus, was identified in Australia in 1994. There have been just seven cases of humans getting infected – four of them were fatal.

    Nipah virus, discovered in Malaysia in 1998, is much more deadly. It has caused 30 outbreaks in south-east Asia, infecting over 600 people, with death rates as high as 100% in some cases.

    These viruses usually cause fever and other serious symptoms, such as brain swelling and difficulty breathing. They are thought to be carried by bats and can spread to humans through their saliva or urine. Horses are also thought to be carriers.

    Thanks to new technology that allows scientists to study the genetics of viruses, they’ve now found nearly 20 species of henipaviruses around the world. These viruses have been found on every continent except Antarctica, including places like Ghana, China, Australia and Brazil. This shows that henipaviruses are probably common in nature, and new ones could pop up almost anywhere.

    For example, in China, a virus called Mojang virus was linked to the deaths of three workers who were exposed to it in a mine. Another virus, Langya, spread by shrews, caused an outbreak in which 35 people got sick – although they all recovered.

    So far, other henipaviruses haven’t caused human infections, but the potential is there.

    The rapid growth in our understanding of these viruses comes from improvements in technology and global efforts to study diseases. But it also reminds us that viruses can suddenly jump from animals to humans in unpredictable ways.

    Whether a virus can harm humans depends on how well it can infect human cells, and how badly it affects the body. Some viruses cause mild symptoms, while others can lead to life-threatening diseases. Studying these viruses requires scientists to look closely at their genetic code and run laboratory tests to understand how they work.

    Henipaviruses can infect many animals, including bats, horses, monkeys, dogs, cats and even rodents. This means they are more adaptable and have a higher chance of jumping from animals to humans in different ways. In comparison, a virus like measles can only infect humans, which makes it less likely to spread to other species.

    No drugs or vaccines … yet

    There is no cure for henipavirus infections, but researchers are working on a vaccine for Nipah virus. Some new treatments, such as monoclonal antibodies, are also being developed but aren’t ready for use yet. This makes Nipah and Hendra viruses major public health concerns. The World Health Organization has called for more research to help fight them.

    While there’s no evidence that Camp Hill virus has infected any humans yet – and the chances of it doing so are low – its discovery in North America is a reminder that viruses can emerge anywhere. Even though shrews usually live in forests and don’t come into much contact with people, the potential for the virus to spread remains a worry.

    The more we learn about these viruses, the better we’ll be at creating vaccines that can protect us from both known and new threats. Keeping up with research and staying prepared is crucial to protecting global health from future outbreaks.

    Shirin Ashraf does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    – ref. Camp Hill virus explained: what are the risks of a henipavirus outbreak in America? – https://theconversation.com/camp-hill-virus-explained-what-are-the-risks-of-a-henipavirus-outbreak-in-america-249183

    MIL OSI – Global Reports –

  • MIL-OSI Global: Struggling with money? Here are 5 tips for growing your income from a financial expert

    Source: The Conversation – Canada – By Lisa Kramer, Professor of Finance, University of Toronto

    Whether you are just starting or looking to advance your financial skills, there are steps you can take to improve your financial situation. (Shutterstock)

    Personal finance can often feel overwhelming, with many Millennial and Gen Z individuals struggling with student loans, the high cost of living, housing market challenges and a general sense of financial anxiety. But just as any challenge can be overcome through skill development and persistence, so can your finances.

    Whether you are just starting or looking to advance your financial skills, there are steps you can take to improve your financial situation. From basic recommendations to more advanced strategies, here are some ways to get yourself on the path to financial stability.

    Ready to make a change? The Quarter Life Glow-up is a new, six-week newsletter course from The Conversation’s UK and Canada editions.

    Every week, we’ll bring you research-backed advice and tools to help improve your relationships, your career, your free time and your mental health – no supplements or skincare required. Sign up here to start your glow-up at any time.

    1. Create a budget

    The first step to mastering your finances is working out where your money is going. You may discover, as my now-husband realized when he was a graduate student, that you’re spending a third of your food expenditures on coffee.

    Once you determine where your money is going, you can reign in some of your expenses and ensure some money is left over each month to devote to debt repayment or savings. Creating a budget is essential for doing this.

    The Government of Canada has an online budget planner tool available, as does the United States Federal Trade Commission and the United Kingdom government’s Money and Pensions Service.

    Once your budget is made, you can focus on reducing discretionary costs and redirect those savings toward your financial goals.

    Create a realistic budget that aligns with your financial goals.
    (Shutterstock)

    2. Boosting your income

    It can be difficult to reduce expenses in an inflationary environment — especially when the cost of basic needs like food and shelter are becoming increasingly expensive in Canada, the United States and elsewhere.

    But you can still find ways to boost your income without necessarily getting a second or third job.



    Read more:
    Maths that will help you as an adult: from baking a cake to asking for a pay rise

    It can be daunting to ask your employer for a raise, but you’re much more likely to get one if you ask. Arm yourself with quantifiable evidence about your productivity and work ethic. Then, rehearse your request with a mentor who is further along on your career path.

    If you don’t succeed on your first try, use the experience to understand how to secure a raise in the future. Another way to get a raise? While still employed — and on your own time, not company time — look for a new job, get an offer and use it as leverage to politely negotiate a raise. If you’re still unsuccessful, it may be time to move on to that new job.

    3. Build your pension

    Older generations are more likely to have worked in jobs that came with defined-benefit pensions, a type of pension plan that provides someone with a stream of income after they retire.

    These days, jobs are less likely to come with such perks. A recent World Bank report found about half of gig workers worldwide have no retirement plan; in some countries, that figure is as high as 75 per cent.

    It’s important to check if your current employer offers a defined contribution pension plan, which involves you and your employer contributing to a saving account that grows over time.

    Even if you don’t have access to such a plan, consider using a robo-advisor to replicate one of its key features by setting up an automatic monthly contribution to an investment account. Then, you can increase the amount you contribute every time you get a raise.

    You should also consider allocating that investment to a well-diversified stock index, or to a blend of stocks and bonds if you are relatively risk averse. An exchange-traded fund, also known as an ETF, is a low-cost way to do this compared to buying mutual funds. While the value of your investment may go up and down over the short term, it is likely to perform well over the long term.

    Talking to a financial advisor is always a good idea if you feel stuck.
    (Shutterstock)

    4. Steady does it

    Once you have set up automatic contributions and established a routine of increasing them over time, you will see your investment account balance start to grow. Even if you can put away only small amounts each month in the beginning, you’ll develop good financial habits.

    Your next task should be avoiding the temptation of timing the ups and downs of financial markets by actively trading. To dodge this common pitfall, avoid examining the balance of your investment account on a month-to-month basis and keep contributing, regardless of whatever may be happening in financial markets.



    Read more:
    If you have money anxiety, knowing your financial attachment style can help

    Ironically, overconfident investors often underperform the market when they try — and fail — to outperform by frequently trading their investment holdings. Successful investors understand the most reliable path to wealth accumulation is paved with a buy-and-hold mentality, meaning you should purchase investments with the intention of keeping them long-term rather than frequently buying and selling.

    5. Imagine the future

    When you’re young, it can be hard to identify with an abstract future version of yourself in retirement. Your golden years may be decades in the future, and it can seem like you have ages to prepare for whatever life will bring you at that stage in life.

    However, research shows that the clearer you can mentally picture your future self, the more motivated you will be to make sensible saving and retirement planning decisions for your future self.

    Try imagining what your life will be like when you’re retired, or what you will look like. Will you have grey hair or wrinkles? How will you spend your time? Picture your future self in retirement and the kind of life you would like to have.

    Meet the challenge head-on

    If you still find yourself overwhelmed by these tips and don’t know where to begin, consider contacting a fee-only financial advisor to analyze your situation and provide you with personalized advice.

    Remember, no matter what financial challenge you may face, it’s simply a new opportunity to overcome. With the right strategies and support, you’ll be able to tackle any financial hurdles and work toward a more secure future for yourself.

    Achieving financial stability is a journey that requires ongoing effort and dedication. Each milestone you reach brings you closer to your ultimate goal.

    Lisa Kramer has received funding from the Social Sciences and Humanities Research Council of Canada and the Canadian Securities Institute Research Foundation.

    – ref. Struggling with money? Here are 5 tips for growing your income from a financial expert – https://theconversation.com/struggling-with-money-here-are-5-tips-for-growing-your-income-from-a-financial-expert-234623

    MIL OSI – Global Reports –

  • MIL-OSI Video: SOAR Team at WORK! | U.S. Army

    Source: US Army (video statements)

    About the U.S. Army:

    The Army Mission – our purpose – remains constant: To deploy, fight and win our nation’s wars by providing ready, prompt & sustained land dominance by Army forces across the full spectrum of conflict as part of the joint force.

    Interested in joining the U.S. Army?
    Visit: spr.ly/6001igl5L

    Connect with the U.S. Army online:
    Web: https://www.army.mil Facebook: https://www.facebook.com/USarmy/ X: https://www.twitter.com/USArmy Instagram: https://www.instagram.com/usarmy/ LinkedIn: https://www.linkedin.com/company/us-army
    #USArmy #Soldiers #Military #SOAR

    https://www.youtube.com/watch?v=_f4Y6deXfUc

    MIL OSI Video –

  • MIL-OSI Security: Saving Lives, Delivering the Future: Heroes in Uniform and Scrubs

    Source: United States Navy (Medical)

    Story by: Chiara M. Caputo

    U.S. Navy Medicine and Training Command (USNMRTC) Sigonella highlights the accomplishments of three remarkable physicians who have dedicated their lives to serving both their patients and their country. These leaders in military medicine embody the values of innovation, resilience, and selfless service.

    Through their tireless efforts, these physicians have not only advanced medical care within the Military Health System but have also paved the way for future generations of leaders in medicine and the armed forces. Each of their stories highlights a profound commitment to excellence and a passion for making a difference, whether on the battlefield, in clinics, or through groundbreaking research.

    We honor their contributions and celebrate their unwavering dedication to health care, military service, and the pursuit of a healthier, stronger future. Through their stories, we hope to inspire future generations and showcase the unwavering commitment of these women in uniform and in diverse roles in Navy Medicine.

    Brandi L Sakai, MD
    Commander, USN
    Board Certified Emergency Medicine Physician

    Born in Welsh, Louisiana, on June 6, 1981, Cmdr. Sakai grew up with a passion for science and the ocean. After graduating from the Louisiana School for Math, Science, and the Arts in 1998, she pursued marine biology, studying diverse ecosystems from the marshes of Louisiana to Scotland’s marine mammals and the vibrant reefs of the Virgin Islands. Her work at the Roy L. Schneider Hospital’s barometric pressure chamber sparked her drive to combine science with service, graduating cum laude with a B.S. in Biology.

    In 2005, she commissioned in the Navy through the Armed Forces Health Professions Scholarship Program (HPSP) and began medical school at Louisiana State University Health Sciences Center. Hurricane Katrina hit during her training, and Commander Sakai worked tirelessly in pop-up clinics, providing care and vaccinations to displaced communities. This experience shaped her dedication to serving others in times of crisis.
    Her Navy career has been marked by leadership and innovation. From integrating Marine medical services in Japan to creating advanced training programs for shock trauma care, she has consistently raised the bar for military medicine. As the Senior Medical Officer in Okinawa and later the Department Head of Emergency Medicine in Guantanamo Bay, she improved operations, ensured top-tier care, and earned recognition for her commitment to excellence.

    Beyond her professional achievements, Commander Sakai is a certified Emergency Medicine Diplomate and a devoted wife and mother of two. When she’s not scuba diving, sailing, or baking, she’s embracing projects that reflect her passion for problem-solving and innovation.

    Reflecting on her career, Cmdr. Sakai shared, “I had many jobs that many would consider a career. I was a PADI scuba instructor and manager of the storefront of a tour operation in St. Thomas US Virgin Islands (USVI). If you took a cruise to the island, you walked past our store on the docks. We may have said hello two decades ago! After doing the job for 5 years, I felt that I had learned all that I could, and there was no chance for advancement based on performance, so I knew that I needed something new and challenging. After getting my degree in Marine Biology and presenting environmental research to the Senate on USVI fisheries and the impact of hotel expansion, I realized that I enjoyed talking and educating people one-on-one, and speaking to rooms and presenting posters wasn’t going to make me happy. I volunteered at the local Emergency Department, and the variety and mental challenge of solving a puzzle on every patient kept me coming back. I decided to turn it into a career, but I also hated to stay in one place (there was a big wide world to explore), so I joined the Navy and never looked back. I did a General Surgery internship, and the Chaplain and I were the only Naval Officers in my first duty with the Marines in Iwakuni, Japan for 3 years. Being part of the Marines for 3 years to start my career really shaped me and set the tone for all my OCONUS tours since. My husband was an Ombudsman and found a great career as a financial educator that allows him to work virtually. If you need advice on mainland Japan, Korea, Okinawa, or Guantanamo Bay, or love medicine and want to explore your options give me a ring.”

    Meagan G. Chauvin, MD, FACOG
    Lieutenant Commander, USN
    Director of Medical Services/Staff Attending OBGYN

    A Houston, Texas native, Lt. Cmdr. Meagan Chauvin has built a remarkable career in military medicine. After earning her Bachelor of Science in Chemistry with Distinction from the U.S. Naval Academy in 2010, she completed her Medical Doctorate at the University of Texas Medical School at Houston in 2014. She completed her Obstetrics and Gynecology residency in 2018 at Naval Medical Center San Diego.

    Her first assignment as a staff OB/GYN took her to Naval Hospital Guam, where she led the OB/GYN Clinic as Department Head and earned Board Certification in Obstetrics and Gynecology. Later, at Fort Belvoir Community Hospital in Virginia, she became Department Chief of the Women’s Health Clinic, further demonstrating her leadership and dedication to women’s health.

    Now serving as the Director of Medical Services at Naval Hospital Sigonella in Italy, Lt. Cmdr. Chauvin continues to lead with excellence. Among her awards are the Defense Meritorious Service Medal and the Navy and Marine Corps Commendation Medal.

    Lt. Cmdr. Chauvin is also a proud wife to Matthew Gerard Chauvin and mom to three children—EJ, Madeline, and Ellie—balancing her professional success with a fulfilling family life. Reflecting on her career, LCDR Chauvin shared, “I was inspired to become an OBGYN, because I loved taking care of women across their lifespan and developing long-term relationships with my patients. In addition, I love welcoming babies into the world and being part of helping patients grow their families. I joined the Navy after being inspired by classmates from high school who also went to service academies. The Naval Academy was an amazing experience that led me to the most important job I can imagine, supporting Navy women and families as an OBGYN. I am proud to follow in the Navy tradition of my great grandfather, who served on a troop transport ship in WWI, and my grandfather, who joined via the Navy V-12 program during WWII.”

    Kristen Shafer, MC
    Lieutenant, USN
    Emergency Medicine Attending

    Born in New York, New York, Lt. Shafer discovered her passion for science and outreach early in life. After earning her bachelor’s degree in chemistry pre-medicine at Indiana University of Pennsylvania in 2014, she brought the wonders of chemistry to life for local elementary students through her self-created Chemistry Magic Show.

    In 2015, she pursued her Master of Science in Space Physiology and Health at King’s College London, where her thesis explored visual function and impairment in dynamic environments. She collaborated with the United Kingdom space program’s Mission X initiative, blending her love of science with public engagement.

    Lt. Shafer joined the Navy through the HPSP program and earned her Doctor of Medicine from Stony Brook University in 2020, graduating early to assist with the initial surge of COVID-19 patients in New York. She went on to complete her Emergency Medicine Residency at USNMRTC Portsmouth in 2024, where she expanded Science, Technology, Engineering, and Math (STEM) outreach programs, inspiring over 300 high school students annually.

    Now an Emergency Medicine Attending at USNMRTC Sigonella, Lt. Shafer continues her commitment to both medicine and mentorship. As Emergency Response Committee Chair, she oversees emergency preparedness, and as a liaison to local DoDEA schools, she is developing a mentorship program to introduce students to healthcare careers and military opportunities.

    With a passion for outreach and academic medicine, LT Shafer embodies the Navy’s mission to serve both on and off the field, inspiring the next generation of leaders. Reflecting on her career in emergency medicine, Lt. Shafer said, “In emergency medicine, we need to be ready for whatever comes in the door at any time. Military medicine lets me practice that medicine and be comfortable providing care not just at any time, but any place in the world and to a population that is dedicated to serving others and making a difference.”

    USNMRTC Sigonella is one of The Defense Health Agency’s Overseas Military Treatment Facilities (MTF). The staff are comprised of active duty service members, General Service (GS), contractors, and Local Nationals. It ensures maximum readiness by providing high-quality, safe patient and family-centered care to maximize force health protection for all beneficiaries, to included NATO and transient DoD forces in the U.S. Fifth Fleet and U.S. Sixth Fleet areas of operation.

    The U. S. Naval Academy (USNA) offers a variety of academic curriculums that prepare their graduates for a rewarding military career. Graduates of the USNA will accept a commission for 5 years of active duty service in the U.S. Navy or Marine Corps. For more information regarding the USNA visit: https://www.usna.edu/homepage.php.

    If you are already in or plan to attend school to be a physician, dentist, optometrist, physician assistant or clinical psychologist, the Armed Forces Health Professions Scholarship Program (HPSP) will pay your educationally based tuition and fees for up to four years of school and provide a monthly stipend paid directly to you. After graduation, you’ll join the Navy’s active duty team as a commissioned officer. In return, you agree to serve a minimum of 2 years on active duty or year for year of scholarship, whichever is longer.

    MIL Security OSI –

  • MIL-OSI USA: Mercer County, W.Va., Disaster Recovery Center closed Feb. 11 due to forecast inclement weather

    Source: US Federal Emergency Management Agency

    Headline: Mercer County, W.Va., Disaster Recovery Center closed Feb. 11 due to forecast inclement weather

    Mercer County, W.Va., Disaster Recovery Center closed Feb. 11 due to forecast inclement weather

    Mercer County, W.Va., Disaster Recovery Center closed Feb. 11 due to forecast inclement weatherCHARLESTON, W.Va.– Due to forecast inclement weather, the FEMA Mercer County Disaster Recovery Center (DRC) in Princeton will be closed on Tuesday, Feb. 11, 2025. The DRC is scheduled to reopen on Wednesday, Feb. 12, 2025. Additional changes based on weather conditions may occur. Please check FEMA’s DRC locator at fema.gov/drc for up-to-date information. The center is located at: Disaster Recovery CenterLifeline Princeton Church of God250 Oakvale Road Princeton, WV 24740 Hours of operation through Feb. 14, 2025:Tuesday, Feb. 11:  ClosedWednesday to Thursday: 9 a.m. to 5 p.m.Friday: 9 a.m. to 12 noonDRCs are accessible to all, including survivors with mobility issues, impaired vision, and those who are who are Deaf or Hard of Hearing.Please note: The deadline to apply for FEMA disaster assistance was Feb. 7, 2025. The DRC operations were extended through Friday, Feb. 14, 2025, to provide Mercer County residents the opportunity to speak face-to-face with staff about their disaster assistance applications.Survivors do not have to visit a DRC to check on the status of their FEMA application. You can call 800-621-FEMA (3362). The toll-free telephone line operates seven days a week. If you use a relay service, such as video relay service (VRS), captioned telephone service or others, give FEMA your number for that service. You can also register online at DisasterAssistance.gov or through the FEMA App on your phone. For more information on West Virginia’s disaster recovery, visit emd.wv.gov, West Virginia Emergency Management Division Facebook page, www.fema.gov/disaster/4851 and www.facebook.com/FEMA.###FEMA’s mission is helping people before, during and after disasters. FEMA Region 3’s jurisdiction includes Delaware, the District of Columbia, Maryland, Pennsylvania, Virginia and West Virginia.Follow us on X at x.com/FEMAregion3 and on LinkedIn at linkedin.com/company/femaregion3.Disaster recovery assistance is available without regard to race, color, religion, nationality, sex, age, disability, English proficiency or economic status. If you or someone you know has been discriminated against, call FEMA toll-free at 833-285-7448. If you use a relay service, such as video relay service (VRS), captioned telephone service or others, give FEMA your number for that service. Multilingual operators are available (press 2 for Spanish and 3 for other languages).
    kelly.magarity
    Tue, 02/11/2025 – 01:38

    MIL OSI USA News –

  • MIL-OSI USA: Sols 4447–4449: Looking Back at the Marker Band Valley

    Source: NASA

    Earth planning date: Friday, Feb. 7, 2025
    We are continuing our merry way alongside “Texoli” butte, heading toward the boxworks feature in the distance, our next major waypoint. This is a series of large-scale ridges, which appear from orbital data to be a complex fracture network.  
    Of course, we don’t actually expect to get there until late fall 2025, at the earliest. Our drives are long right now (the weekend plan has a 50-meter drive, or about 164 feet) but we are still taking the time to document all of the wonderful geology as we go, and not just speeding past all of the cool things! 
    As Conor mentioned in Wednesday’s blog, power is becoming a challenge right now. Those of us in the northern hemisphere might be thinking (eagerly anticipating!) about the return of Spring but Mars is heading into colder weather, meaning we need to use more power for warming up the rover. However, we are also in a very interesting cloud season (as Conor mentioned), so the environmental theme group (ENV) are keen to do lots of imaging right now. This means very careful planning and negotiating between ENV and the geology theme group (GEO) to make the most of the power we do have. Luckily, this plan has something for everyone. 
    The GEO group was handed a weekend workspace containing a jumble of rocks — some layered, some not. None of the rocks were very large but we were able to plan APXS and MAHLI on a brushed rock surface at “Aliso Canyon” and on a small, flat unbrushed target, “Bridge to Nowhere,” close to the rover. ChemCam will use the LIBS laser to shoot three bedrock targets, sampling regular bedrock at “Newcomb,” some cracked bedrock at “Devore” and some of the more layered material at “Rubio Canyon.” Mastcam will document the ChemCam LIBS targets. In addition to the cloud imaging, we have lots of other imaging in this plan. We are in position right now to look back down at the “Marker Band Valley,” which we first entered almost a thousand sols ago! Before we go too much further along the side of Texoli butte and lose sight of the Marker Band Valley for some time, both ChemCam and Mastcam will take advantage of this to image the Marker Band Valley and the “Marker Band.” Other images include ChemCam remote images of cap rocks in the distance and two Mastcams of near-field (i.e., close to the rover) troughs.
    Written by Catherine O’Connell-Cooper, Planetary Geologist at University of New Brunswick

    MIL OSI USA News –

  • MIL-OSI USA: Mount Everest from Space

    Source: NASA

    Crew aboard space shuttle Columbia captured this image of Mount Everest on Nov. 30, 1996, during the STS-80 mission. STS-80, the final shuttle flight of 1996, was highlighted by the successful deployment, operation, and retrieval of two free-flying research spacecraft.
    See more photos from this mission.
    Image credit: NASA

    MIL OSI USA News –

  • MIL-OSI USA: NASA Awards Launch Service Task Order for Pandora Mission

    Source: NASA

    NASA has selected SpaceX of Starbase, Texas, to provide the launch service for the agency’s Pandora mission, which will study at least 20 known exoplanets and their host stars to find out how changes in stars affect our observations of exoplanet atmospheres.
    The selection is part of NASA’s Venture-Class Acquisition of Dedicated and Rideshare (VADR) launch services contract. This contract allows the agency to make fixed-price indefinite-delivery/indefinite-quantity awards during VADR’s five-year ordering period, with a maximum total value of $300 million across all contracts.
    During its one-year primary mission, Pandora will observe each exoplanet 10 times, observing for 24 hours each visit. It will capture critical data about the planet and its host star during transits, an event where a planet crosses in front of the star it orbits.
    The satellite will use an innovative 17-inch (45-centimeter)-wide all-aluminum telescope to simultaneously measure the visible and near-infrared brightness of the host star and obtain near-infrared spectra of the transiting planet. This will allow scientists to cleanly separate star and planetary signals, knowledge that will enhance observations from NASA’s James Webb Space Telescope and future missions searching for habitable worlds, like the agency’s Habitable Worlds Observatory.
    Pandora is a joint effort between NASA’s Goddard Space Flight Center in Greenbelt, Maryland, and Lawrence Livermore National Laboratory in California. The Astrophysics Pioneers program, from the Astrophysics Division at NASA Headquarters in Washington, funds Pandora and other astrophysics science missions using smaller, lower cost hardware and payloads. NASA’s Launch Services Program, based at the agency’s Kennedy Space Center in Florida, manages the VADR contract.
    To learn more about NASA’s Pandora mission, visit:

    Pandora

    -end-
    Tiernan DoyleHeadquarters, Washington202-358-1600tiernan.doyle@nasa.gov
    Patti BiellingKennedy Space Center, Florida321-501-7575patricia.a.bielling@nasa.gov

    MIL OSI USA News –

  • MIL-OSI USA: Station Science Top News: Feb. 7, 2025

    Source: NASA

    Measuring water loss from space
    This study showed that the International Space Station’s ECOSTRESS instrument estimates of evapotranspiration (transfer of water to the atmosphere from Earth’s surface and plants) are comparable to ground-based reference values. This finding suggests space measurements could provide guidance for improved water management on large scales.
    Worsening droughts due to climate change require better water management. Evapotranspiration is a critical part of the hydrologic cycle, but data are lacking on local water conditions and demands. California’s Eastern Municipal Water District uses the ground-based California Irrigation Management Information System to track evapotranspiration, but it has limited spatial coverage and consistency. Space-based estimates could be better and more consistent.

    Four-legged robotic retrievers
    Space station crew members successfully located and retrieved an object in a simulated Mars environment using a remotely controlled four-legged robot, Bert. Legged robots could provide the ability to explore and survey different extraterrestrial surfaces on future missions.
    On uneven lunar and planetary surfaces, robots with legs could explore areas inaccessible to wheeled rovers. Surface Avatar, an investigation from ESA (European Space Agency), evaluated remote control of multiple robots in space, providing information on how human operators respond to physical feedback (such as feeling a bump when a robot arm makes contact) and identifying challenges for orbit-to-ground remote operation of robots. The German Aerospace Center is developing Bert.

    Technology supports atmospheric studies
    Researchers found that the Compact Thermal Imager (CTI) on the space station produced scientifically useful imagery of atmospheric phenomena, including gravity waves, clouds, and volcanic plumes. This technology could change current practices and instrument design for remote sensing of Earth from space.
    The CTI is mounted on hardware for Robotic Refueling Mission 3, which tested technology for the robotic transfer and storage of cryogenic fluids in microgravity. The station’s orbit provides near-global coverage and CTI has reduced size, energy use, and cost. Its images can measure fires, ice sheets, glaciers, and snow surface temperatures on the ground and the transfer of water from soil and plants into the atmosphere.

    MIL OSI USA News –

  • MIL-OSI USA: Winter Weather Threat This Week: Get Ready Now

    Source: US Federal Emergency Management Agency

    Headline: Winter Weather Threat This Week: Get Ready Now

    Winter Weather Threat This Week: Get Ready Now

    CHICAGO – With the threat starting midweek of heavy snowfall and cold temperatures across much of the upper Midwest, FEMA’s Region 5 office in Chicago encourages everyone to prepare now. “The forecast this week is an important reminder that winter isn’t over just yet,” said acting FEMA Region 5 Regional Administrator Michael S. Chesney. “Now is the time to check local weather forecasts and warnings, learn the risks for your area and take precautions to stay safe.”Follow the instructions of state and local officials and listen to local radio or TV stations for updated emergency information.Gather supplies in case you need to stay home for several days without power. Keep in mind each person’s specific needs, including medication, and don’t forget the needs of your pets. Fully charge your phone and other electronic items before the storm in case you lose power.Avoid non-essential travel. If you must go out, make sure your vehicle is in good working condition and fill your gas tank before the storm hits. Check that your car’s emergency supply kit is fully stocked before traveling.Limit your time outside. If you need to go outside, wear layers of warm clothing. Watch for signs of frostbite and hypothermia.Heat your home safely. Remember to keep space heaters at least three feet away from items that can burn and plug them directly into the wall. Never use a gas stovetop or oven to heat your home. When using a generator, always keep it outdoors and at least 20 feet away from windows, doors and attached garages.Find even more valuable tips to help you prepare for severe winter weather by visiting #WinterReady | Ready.gov. 
    kimberly.keblish
    Mon, 02/10/2025 – 20:49

    MIL OSI USA News –

  • MIL-OSI USA: Office of the Governor — News Release — Maui Wildfires Settlement Will Move Forward According to Hawai‘I Supreme Court Decision

    Source: US State of Hawaii

    Office of the Governor — News Release — Maui Wildfires Settlement Will Move Forward According to Hawai‘I Supreme Court Decision

    Posted on Feb 10, 2025 in Latest Department News, Newsroom, Office of the Governor Press Releases

    STATE OF HAWAIʻI 
    KA MOKU ʻĀINA O HAWAIʻI 
     
    JOSH GREEN, M.D. 
    GOVERNOR
    KE KIAʻĀINA 
     

    MAUI WILDFIRES SETTLEMENT WILL MOVE FORWARD ACCORDING TO HAWAI‘I SUPREME COURT DECISION 
     

    FOR IMMEDIATE RELEASE
    February 10, 2025

    HONOLULU – In a unanimous decision today, the Hawaiʻi Supreme Court ruled against insurance companies and in favor of the state, to allow the $4 billion dollar Maui wildfires litigation settlement to move forward.

    Insurance companies had refused to enter into a settlement with the defendants, claiming that they had the right to make claims against the defendants, including the state of Hawaiʻi, to recoup what was paid out to the fire victims, a process referred to as subrogation.

    All five Hawai‘i Supreme Court justices said in their written order that the exclusive remedy, under HRS 663-10, is for the property and casualty insurer to request the money paid out to be reimbursed by the insured. The settlement monies from the defendants will go directly to fire victims rather than to the insurance companies.

    “As Governor of Hawai‘i, I welcome the state Supreme Court’s unanimous decision to uphold the $4 billion Maui wildfire settlement. We reached this historic settlement for the wildfire survivors on Maui through a collaborative effort to do what is right (pono), for our people, consistent with our values,” said Governor Josh Green, M.D. “The settlement came exactly one year after the fire occurred, when most felt it could take five years or more to reach agreement. Today’s decision will help our people heal much sooner, as we continue to rebuild and recover.”

    Governor Green went on to say, “Going forward I will continue to work with all parties, including those who opposed the settlement, to expedite our critical recovery as a people and a state.”

    “We are very pleased that this hurdle to resolving the claims of the fire victims has been cleared,” said Attorney General Anne Lopez.

    The case was remanded to the Circuit Court of the Second Circuit for further proceedings. The Supreme Court decision can be found here.

    # # # 

    Media Contacts:   
    Erika Engle
    Press Secretary
    Office of the Governor, State of Hawai‘i
    Phone: 808-586-0120
    Email: [email protected]

    Makana McClellan
    Director of Communications
    Office of the Governor, State of Hawaiʻi
    Cell: 808-265-0083
    Email: [email protected]

    MIL OSI USA News –

  • MIL-OSI USA: California launches dashboard to track LA recovery, adds new services finder to connect firestorm survivors with resources

    Source: US State of California 2

    Feb 10, 2025

    What you need to know: The state continues to upgrade CA.gov/LAfires to provide more resources and information for firestorm survivors. 

    LOS ANGELES – Governor Gavin Newsom today announced new efforts to provide accountability with ongoing Los Angeles firestorm recovery efforts and support firestorm survivors.

    California launched a new dashboard on the CA.gov/LAfires website to track recovery efforts for Los Angeles – including data on people helped, debris removal, schools, water systems and air quality. Additionally, the state launched a new recovery services finder tool that helps survivors and businesses connect with state and federal resources, including housing, individual assistance, personal document replacement, employment, and more. 

    The new features build on the CA.gov/LAfires website, which was rapidly launched in the days following the start of the firestorms, and soon after was significantly overhauled to better integrate with in-person Disaster Recovery Centers. 

    Since its launch, there have been over 550,000 visits to the website. This latest update means impacted Californians can access all of the same resources offered at Disaster Recovery Centers – completely online.   

    We’re moving faster than ever to ensure survivors of these firestorms have all the resources they need to recover. And for the first time, survivors can access all the services available at in-person centers completely online. Not only that – we’re now tracking recovery efforts in real-time to hold ourselves and all levels of government accountable for delivering for Angelenos.

    Governor Gavin Newsom

    Governor Newsom directed the Government Operations Agency, in collaboration with the California Department of Technology and the Office of Data and Innovation, to improve the digital experience after hearing directly from survivors on the ground about their needs.  

    “I commend the dedicated teams at CDT and ODI for coming together, creating a plan and executing the launch of this survivor resource,” said Government Operations Agency Secretary Amy Tong. “The outcome of this was solely focused on how to get survivors what they need, and the team was laser focused on making the new site work for them.” 

    Historic recovery and rebuilding efforts — faster than ever before 

    • Cutting red tape to help rebuild Los Angeles faster and stronger. Governor Newsom issued an executive order to streamline the rebuilding of homes and businesses destroyed — suspending permitting and review requirements under the California Environmental Quality Act (CEQA) and the California Coastal Act. The Governor also issued an executive order further cutting red tape by reiterating that permitting requirements under the California Coastal Act are suspended for rebuilding efforts and directing the Coastal Commission not to issue guidance or take any action that interferes with or conflicts with the Governor’s executive orders. The Governor also issued an executive order removing bureaucratic barriers, extending deadlines, and providing critical regulatory relief to help fire survivors rebuild, access essential services, and recover more quickly.
    • Providing tax and mortgage relief to those impacted by the fires. California postponed the individual tax filing deadline to October 15 for Los Angeles County taxpayers. Additionally, the state extended the January 31, 2025, sales and use tax filing deadline for Los Angeles County taxpayers until April 30 — providing critical tax relief for businesses. Governor Newsom suspended penalties and interest on late property tax payments for a year, effectively extending the state property tax deadline. The Governor also worked with state– and federally-chartered banks that have committed to providing mortgage relief for survivors in certain zip codes.
    • Fast-tracking temporary housing and protecting tenants. To help provide necessary shelter for those immediately impacted by the firestorms, the Governor issued an executive order to make it easier to streamline construction of accessory dwelling units, allow for more temporary trailers and other housing, and suspend fees for mobile home parks. Governor Newsom also issued an executive order that prohibits landlords in Los Angeles County from evicting tenants for sharing their rental with survivors displaced by the Los Angeles-area firestorms.
    • Mobilizing debris removal and cleanup. With an eye toward recovery, the Governor directed fast action on debris removal work and mitigating the potential for mudslides and flooding in areas burned. He also signed an executive order to allow expert federal hazmat crews to start cleaning up properties as a key step in getting people back to their properties safely. The Governor also issued an executive order to help mitigate risk of mudslides and flooding and protect communities by hastening efforts to remove debris, bolster flood defenses, and stabilize hillsides in affected areas. 
    • Safeguarding survivors from price gouging. Governor Newsom expanded restrictions to protect survivors from illegal price hikes on rent, hotel and motel costs, and building materials or construction. Report violations to the Office of the Attorney General here.
    • Directing immediate state relief. The Governor signed legislation providing over $2.5 billion to immediately support ongoing emergency response efforts and to jumpstart recovery efforts for Los Angeles. California quickly launched CA.gov/LAfires as a single hub of information and resources to support those impacted and bolsters in-person Disaster Recovery Centers. The Governor also launched LA Rises, a unified recovery initiative that brings together private sector leaders to support rebuilding efforts. Governor Newsom announced that individuals and families directly impacted by the recent fires living in certain zip codes may be eligible to receive Disaster CalFresh food benefits.
    • Getting kids back in the classroom. Governor Newsom signed an executive order to quickly assist displaced students in the Los Angeles area and bolster schools affected by the firestorms.
    • Protecting victims from real estate speculators. The Governor issued an executive order to protect firestorm victims from predatory land speculators making aggressive and unsolicited cash offers to purchase their property.
    • Helping businesses and workers get back on their feet. The Governor issued an executive order to support small businesses and workers, by providing relief to help businesses recover quickly by deferring annual licensing fees and waiving other requirements that may impose barriers to recovery.

    Press Releases, Recent News

    Recent news

    Feb 10, 2025

    News What you need to know: The state and federal government are working at record-pace to remove debris from the Los Angeles area firestorms. LOS ANGELES – The State of California, in coordination with federal and local partners, is rapidly advancing wildfire cleanup…

    Feb 10, 2025

    News What you need to know: Governor Newsom is sponsoring new legislation to allow homeowners who receive insurance payments for lost or damaged property to receive the interest accrued rather than lenders.  LOS ANGELES — As part of the state’s ongoing efforts to…

    Feb 7, 2025

    News SACRAMENTO – Governor Gavin Newsom today announced the following appointments:Khalil “KC” Mohseni, of Sacramento, has been appointed Commissioner of the California Department of Financial Protection and Innovation, where he has been the Chief Deputy Director…

    MIL OSI USA News –

  • MIL-OSI Asia-Pac: LOGISTICS PERFORMANCE INDEX

    Source: Government of India (2)

    Posted On: 11 FEB 2025 4:08PM by PIB Delhi

    As per the World Bank’s Logistics Performance Index (LPI), 2023 India moved up to 22nd Rank in the Global Ranking in International Shipments category and the Overall 38th Rank in Logistics Performance Index score. Indian Ports have registered quantum improvement in “Turn Around Time”. Global comparison of Indian Ports on “Turn Around Time” parameter, as published in World Bank’s Logistics Performance Index (LPI) Report-2023, acknowledges Indian Ports “Turn Around Time” as 0.9 days which is better than USA (1.5 days), Australia (1.7 days), Belgium (1.3 days), Canada (2.0 days), Germany (1.3 days), UAE (1.1 days), Singapore (1.0 days), Russian Federation (1.8 days), Malaysia (1.0 days), Ireland (1.2 days), Indonesia (1.1 days), New Zealand (1.1 days) and South Africa (2.8 days).

    The Maritime Amrit Kaal Vision 2047 was developed in alignment with the principles of the blue economy. It outlines long-term aspirations for India’s maritime sector and provides a broad action plan for implementation. The vision aims to transform the sector through various key initiatives, including the expansion of port capacity through greenfield and brownfield developments, enhancing operational efficiency by leveraging automation and digitization, and making the sector more sustainable through green initiatives such as the development of hydrogen hubs. In addition to sustainability, the vision emphasizes the development of islands and the cruise sector, aiming to boost coastal tourism and related infrastructure. It also focuses on strengthening maritime capacity building by enhancing workforce training and skill development. Furthermore, the vision aspires to elevate India’s global maritime presence by increasing participation in international maritime platforms. Another critical area of focus is the shipbuilding and repair sector. The vision seeks to position India as a global leader in shipbuilding while also working toward increasing the country’s shipping tonnage. To achieve these ambitious objectives, the strategy proposes a comprehensive set of interventions spanning infrastructure development, policy reforms, technological advancements, institutional strengthening, and regulatory enhancements.

    GMIS 2023 attracted investment commitment of ₹10 lakh crore. This includes signing of 360 MoUs, with an investment commitment of ₹8.35 lakh crore (including international collaborations), and the announcement of additional investible projects worth ₹1.68 lakh crore.

    This information was given by the Union Minister for Ports, Shipping and Waterways, Shri Sarbananda Sonowal in Rajya Sabha, today.

    ***

    G.D. Hallikeri/Henry

    (Release ID: 2101760) Visitor Counter : 42

    MIL OSI Asia Pacific News –

  • MIL-OSI Asia-Pac: WAVES 2025 “Reel Making” Challenge

    Source: Government of India

    Posted On: 11 FEB 2025 3:48PM by PIB Delhi

    Shaping the Future of Storytelling, One Reel at a Time

     

    Introduction

    The WAVES 2025 “Reel Making” Challenge is a unique competition that empowers creators and enthusiasts to showcase their storytelling skills using Meta’s tools through a concise 30-90 second film format. Organised by the Internet and Mobile Association of India in partnership with the Ministry of Information and Broadcasting, the challenge has received an overwhelming response, with 3,379 registrations from across India and 20 countries as of February 5, 2025. It provides a platform for digital creators to experiment, innovate, and push the boundaries of short-form content.

    This challenge is part of the Create in India Challenges, a flagship initiative under the World Audio Visual & Entertainment Summit (WAVES), which will be held from 1st to 4th May 2025 at Jio World Convention Centre & Jio World Gardens, Mumbai. WAVES is a premier global platform fostering discussions, collaboration, and innovation in the Media & Entertainment (M&E) industry. Bringing together industry leaders and stakeholders, the summit will explore emerging opportunities, address challenges, and strengthen India’s position as a global creative hub. With over 70,000 registrations across 31 competitions, the Create in India Challenges continue to fuel creativity, talent, and international participation.

    WAVES 2025: Uniting Creators Worldwide

    The “Reel Making” Challenge, launched as a key initiative under WAVES 2025, underscores India’s emergence as a global hub for media and entertainment while reflecting the rapid growth of its digital creator economy. It aligns with the Government of India’s “Create in India” vision, fostering talent from across the nation and beyond.

    The challenge has attracted notable international participation from countries including Afghanistan, Albania, the United States, Andorra, Antigua and Barbuda, Bangladesh, UAE, Australia, and Germany, among others. This global reach highlights India’s increasing influence in the creative sector and the growing appeal of WAVES as a premier platform for content creators worldwide.

    Domestically, entries have come from diverse and remote locations across India, such as Tawang (Arunachal Pradesh), Dimapur (Nagaland), Kargil (Ladakh), Leh, Shopian (Kashmir), Port Blair (Andaman & Nicobar Islands), Teliamura (Tripura), Kasaragod (Kerala), and Gangtok (Sikkim). The strong response from smaller towns and emerging creative hubs showcases India’s rich storytelling traditions and thriving digital ecosystem.

    Participants above the age of 20 are required to create reels on themes such as “Viksit Bharat,” highlighting India’s technological and infrastructure advancements, and “India @ 2047,” envisioning the nation’s future growth. These themes provide a platform for storytellers to capture India’s innovation journey, demonstrating their creativity and vision for the country’s progress.

     

    Themes

     

    1. Food: Celebrate India’s rich culinary heritage, from street food delights to regional specialties.

     

    1. Travel: Capture India’s breathtaking landscapes, iconic landmarks, and hidden gems.

     

    1. Fashion: Explore the fusion of traditional and modern Indian fashion.

     

    1. Dance & Music: Showcase India’s vibrant rhythms, from classical performances to contemporary beats.

     

    1. Gaming: Dive into India’s evolving gaming culture and its impact on entertainment.

     

    1. Yoga & Wellness: Highlight the essence of holistic living through yoga, Ayurveda, and well-being practices.

     

    1. Road Trips: Share the thrill of Indian road trips, scenic routes, and travel adventures.

     

    1. Tech: Unleash creativity with AR, VR, and digital innovations shaping the future.

    Rules

    Reel Guidelines

    Rewards & Recognition

     

    1. Exclusive invitation to a Meta-hosted event and a reels masterclass in 2025.

     

    1. All-expenses-paid access to the WAVES event.

     

    1. Winning reels featured in the WAVES Hall of Fame, official website, and social media.

     

    1. Ministry-backed support for finalists to compete in global content creator competitions.

     

      

    References:

    https://wavesindia.org/challenges-2025

    https://eventsites.iamai.in/Waves/reelmaking/

    https://pib.gov.in/PressReleaseIframePage.aspx?PRID=2099990

     Click here to download PDF

    ****

    Santosh Kumar/ Sarla Meena/ Saurabh Kalia

    (Release ID: 2101742) Visitor Counter : 39

    MIL OSI Asia Pacific News –

  • MIL-OSI Europe: Written question – Denouncing Trump’s unacceptable proposal for mass expulsion of Palestinians from the Gaza Strip – E-000449/2025

    Source: European Parliament

    Question for written answer  E-000449/2025
    to the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy
    Rule 144
    Lefteris Nikolaou-Alavanos (NI), Kostas Papadakis (NI)

    US President Donald Trump made an unacceptable statement about the Palestinians of Gaza, claiming that he would prefer that certain Arab countries get involved and build housing in a different area where they can perhaps live peacefully. He bluntly confessed to the plan of the occupying state of Israel and the USA — after the genocide — to displace the Palestinians from their land permanently. He even proposed the expulsion of Palestinians to Jordan and Egypt, which would mean the final displacement and occupation-colonisation of the Palestinian territories by Israel.

    Despite thousands of murders and Israel’s criminal policy marked by the genocide of the Palestinians, the EU and governments, including the New Democracy government in Greece, still today maintain commercial, military and political relations with Israel, and the EU-Israel Association Agreement remains in force.

    In view of the above, can the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy answer the following:

    • 1.What is her position on Trump’s unacceptable proposal to displace Palestinians from the territories and transfer them to other countries so that Israel can continue its occupation of Palestinian territories, which is part of Israel’s broader plan for the genocide and displacement of Palestinians?
    • 2.What is her position on the request to cease here and now the EU-Israel Association Agreement and all economic, military and political cooperation with the occupying state of Israel that contributes to the suffering experienced by the people of Palestine?

    Submitted: 3.2.2025

    Last updated: 11 February 2025

    MIL OSI Europe News –

  • MIL-OSI Europe: Written question – Exacerbation of industrial relocation driven by EU policy through US tariffs – P-000555/2025

    Source: European Parliament

    Priority question for written answer  P-000555/2025
    to the Commission
    Rule 144
    Petra Steger (PfE)

    On 1 February 2025, US President Donald Trump signed a decree imposing tariffs of 25 % on imports from Canada and Mexico and 10 % on imports from China. In exchange for border security measures and measures against Mexican drug cartels, Trump’s punitive tariffs were temporarily suspended a few hours before entry into force for Canada and Mexico. However, shortly thereafter Trump let it be known that he would also ‘definitively’ impose import duties on EU products and do so ‘pretty soon’. This would constitute an economic disaster of gigantic proportions for the Union, as our industry is already suffering from the political and bureaucratic excesses of the failed EU Green Deal and is also burdened by the high energy costs in the Union resulting from the failed EU sanctions regime. As Commission President von der Leyen has already announced a strong response to potential US tariffs, industry fears premature knee-jerk measures that could escalate the situation.

    • 1.What measures, concessions or talks has the Commission initiated to prevent an imminent trade war with the US?
    • 2.Is the Commission planning any other countermeasures in addition to tariffs?
    • 3.What measures is the Commission planning to restore the Union to international competitiveness?

    Submitted: 6.2.2025

    Last updated: 11 February 2025

    MIL OSI Europe News –

  • MIL-OSI Europe: MOTION FOR A RESOLUTION on the further deterioration of the political situation in Georgia – B10-0107/2025

    Source: European Parliament

    B10‑0107/2025

    European Parliament resolution on the further deterioration of the political situation in Georgia

    (2025/2522(RSP))

    The European Parliament,

    – having regard to its previous resolutions on Georgia, in particular that of 28 November 2024 on Georgia’s worsening democratic crisis following the recent parliamentary elections and alleged electoral fraud[1],

    – having regard to the European Council conclusions of 14 and 15 December 2023 and of 27 June 2024,

    – having regard to the Commission communication of 8 November 2023 entitled ‘2023 Communication on EU Enlargement Policy’ (COM(2023)0690) and to the accompanying Commission staff working document of 8 November 2023 entitled ‘Georgia 2023 Report’ (SWD(2023)0697),

    – having regard to the joint statement of 8 November 2023 by the Chair of the Delegation for relations with the South Caucasus and the European Parliament’s Standing Rapporteur on Georgia on the Commission recommendation of 8 November 2023 on the EU membership application of Georgia,

    – having regard to the Association Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and Georgia, of the other part[2], which entered into force on 1 July 2016,

    – having regard to the Treaty on the Functioning of the European Union, in particular Article 215(2) thereof, and to the Treaty on European Union, in particular Article 29 thereof,

    – having regard to the Independent International Fact-Finding Mission on the Conflict in Georgia and to its September 2009 report,

    – having regard to the final conclusions of the international election observation mission relating to the parliamentary elections of 26 October 2024,

    – having regard to Rule 136(2) of its Rules of Procedure,

    A. whereas the exercise of freedom of opinion, expression, association and peaceful assembly is a fundamental right enshrined in the Georgian constitution;

    B. whereas Georgia, as a signatory to the Universal Declaration of Human Rights and the European Convention on Human Rights and a member of the Council of Europe and the Organization for Security and Co-operation in Europe (OSCE), has committed itself to the principles of democracy, the rule of law and respect for fundamental freedoms and human rights;

    C. whereas Russia has illegally occupied Abkhazia and South Ossetia since the August 2008 conflict that followed Georgia’s attack on Tskhinvali on the night of 7 to 8 August 2008;

    D. whereas in June 2014, the EU and Georgia signed an Association Agreement that entered into force on 1 July 2016;

    E. whereas in December 2023, the European Council granted Georgia the status of EU candidate country;

    F. whereas in March 2017, the EU visa facilitation agreement with Georgia came into effect, following Georgia’s successful implementation of all the benchmarks set in its visa liberalisation action plan;

    G. whereas on 27 January 2025, the Council decided to suspend parts of the EU-Georgia visa facilitation agreement, specifically affecting diplomats and officials, who may now be required to apply for a visa when travelling to the EU;

    H. whereas on 28 November 2024, in response to the European Parliament’s November 2024 resolution on Georgia, Prime Minister Irakli Kobakhidze announced that Georgia would suspend accession talks until the end of 2028 and refuse all EU budget support; whereas he also stated that by 2028, Georgia would be ‘more prepared than any other candidate country to open accession talks with Brussels and become a Member State in 2030’;

    I. whereas the parliamentary elections held on 26 October 2024 were the first to take place in Georgia under a fully proportional electoral system and were also the first elections to be held since Georgia was granted the status of EU candidate country in December 2023;

    J. whereas the legal framework in Georgia provides an adequate basis for conducting democratic elections, but several long-standing recommendations of the OSCE’s Office for Democratic Institutions and Human Rights (ODIHR) and the Venice Commission remain unaddressed, despite numerous reforms;

    K. whereas on 16 November 2024, the Georgian electoral authority announced the official results of the country’s parliamentary elections, confirming that the ruling Georgian Dream party had won 89 seats in the 150-seat parliament after receiving 53.93 % of the vote, while four opposition parties had passed the 5 % threshold and had received a combined 37.44 % share of the vote;

    L. whereas the international election observation mission on the parliamentary elections in Georgia comprised 529 observers from 42 countries, including 380 expert observers deployed by the ODIHR, 60 parliamentarians and staff from the OSCE Parliamentary Assembly, 39 from the Parliamentary Assembly of the Council of Europe, 38 from the NATO Parliamentary Assembly and 12 from the European Parliament;

    M. whereas the election campaign in Georgia was competitive and generally allowed contestants to campaign freely, but was marred by the use of highly divisive rhetoric and imagery, as well as isolated incidents of violence, event disruptions, verbal abuse and the destruction of campaign materials, as reported by both ruling and opposition parties;

    N. whereas the administration of the elections was generally orderly, but they took place in a tense environment, with overcrowding in many polling stations and several incidents of physical altercations and intimidation;

    O. whereas President Salome Zourabichvili publicly accused the Georgian Government of electoral fraud and irregularities in the recent parliamentary elections; whereas President Zourabichvili subsequently refused to testify before the Georgian Prosecutor’s Office regarding these allegations;

    P. whereas Mikheil Kavelashvili was sworn in as President of Georgia on 29 December 2024; whereas the outgoing President, Salome Zourabichvili, refused to step down despite the official end of her term of office; whereas opposition parties boycotted the Georgian Parliament in protest;

    Q. whereas Georgia has over 26 000 non-governmental organisations (NGOs) – 1 for every 142 citizens, which is greater than the EU average;

    R. whereas following the 2020 parliamentary elections, the NGO International Society for Fair Elections and Democracy, which received external funding, challenged the official election results and questioned their legitimacy, but later admitted that it had made a significant error in its calculations;

    S. whereas the Parliament of Georgia adopted the ‘transparency of foreign influence’ law, which was signed into law on 3 June 2024 despite the President’s veto; whereas the law was met with protest from parts of Georgian civil society; whereas the law requires organisations receiving more than 20 % of their funding from overseas to register as ‘agents of foreign influence’;

    T. whereas on 17 September 2024, the Parliament of Georgia adopted the ‘family values and the protection of minors’ law, which bans gender transition, prohibits adoption by gay and transgender people, nullifies, on Georgian territory, same-sex marriages performed abroad, and provides a legal basis for the authorities to outlaw Pride events and public displays of the LGBTQI+ rainbow flag and to impose the censorship of films and books;

    U. whereas the Venice Commission stresses that, in accordance with international standards, the state has a positive obligation to ensure gender equality; whereas on 4 April 2024, the Parliament of Georgia repealed the 2020 amendments introducing gender quotas for candidate lists in parliamentary and local elections, and abolished the associated financial incentives for political parties;

    V. whereas the United States Agency for International Development (USAID) has been operating in Georgia since 1992; whereas Georgian Prime Minister Irakli Kobakhidze claimed that USAID funding was not directed toward genuine humanitarian objectives but was instead being used to ‘stage revolutions, sow disorder and destabilise countries, including Georgia’; whereas US President Donald Trump implemented a 90-day freeze on US foreign assistance to reassess its alignment with national interests;

    1. Recalls that the EU accession process is based on objective criteria; regrets the European Council’s decision to suspend financial assistance to Georgia; underlines the benefits of the visa facilitation agreement and the need to maintain it; emphasises the need for a constructive dialogue between the Government of Georgia and the EU; calls on the Government of Georgia to uphold its commitments to reform and continue implementing the necessary measures for its EU accession process;

    2. Stresses that Georgia’s future must be determined by the will of its people, free from external pressure or interference; emphasises that Georgia’s sovereignty and political trajectory should reflect the aspirations of its citizens; condemns any attempts, whether foreign or domestic, to undermine Georgia’s democratic institutions;

    3. Takes note of the final report of the international election observation mission, which stated that the overall legal framework in Georgia provides an adequate basis for conducting democratic elections, that voters were offered a wide choice of 18 candidate lists, that contestants could generally campaign freely and that the administration of the elections was generally orderly; is alarmed that these elections took place in a polarised environment and on an uneven playing field, and that there were reports of pressure on voters and cases where ballot secrecy was potentially compromised;

    4. Takes note of the results of the parliamentary elections that took place in Georgia on 26 October 2024; calls on all sides to work together constructively and peacefully and observe the rule of law, and to address the long-standing recommendations of the ODIHR and the Venice Commission with regard to elections and the increasing polarisation of Georgian society; calls for the EU to enter into a holistic and purposeful dialogue with the new Government of Georgia; calls on all foreign actors to respect the outcome of the elections;

    5. Rejects, with deep concern, the adoption of the ‘family values and the protection of minors’ law, and considers it an attack on the LGBTQI+ community and a threat to civil liberties as a whole; rejects, furthermore, the law’s implications for the media, given that it imposes censorship by banning broadcasters from reporting freely on LGBTQI+ issues; reiterates that media freedom and tolerance towards sexual minorities are key features of a functioning democracy;

    6. Notes that the ‘transparency of foreign influence’ law entails the risk that NGOs, civil society organisations, opposition media outlets and other organisations that receive funds from other countries will be labelled ‘foreign agents’;

    7. Emphasises that the rights to freedom of expression and assembly and to peaceful protest are fundamental freedoms and must be respected in all circumstances; expresses concern over reports of the unnecessary and disproportionate use of force against demonstrators; highlights the statement by the UN High Commissioner for Human Rights, Volker Türk, that ‘[a]ny restrictions to these rights must abide by principles of legality, necessity and proportionality’ and that ‘[t]he use of force during protests should always be exceptional and a measure of last resort when facing an imminent threat’;

    8. Emphasises that foreign assistance for humanitarian and development purposes must be allocated on the basis of need and human dignity, not geopolitical interests; stresses that such aid should remain impartial, transparent and focused on social and economic well-being, rather than serving as a tool for political leverage or interference;

    9. Regrets the Georgian Parliament’s decision to abolish mandatory gender quotas; reiterates the need for balanced gender representation in political participation; regrets the under-representation of women in the electoral process; calls on the Government of Georgia to undertake initiatives in this regard;

    10. Takes note of Russian Foreign Minister Sergey Lavrov’s statements at a press conference at the UN General Assembly in New York and the corresponding willingness of Georgian officials to resolve outstanding issues in a peaceful, diplomatic way; encourages both sides to undertake solid initiatives to this end;

    11. Instructs its President to forward this resolution to the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy, the Council, the Commission, the governments and parliaments of the Member States, the Council of Europe, the Organization for Security and Co-operation in Europe and the President, Government and Parliament of Georgia.

     

     

    MIL OSI Europe News –

  • MIL-OSI: Royalty Pharma Reports Q4 and Full Year 2024 Results

    Source: GlobeNewswire (MIL-OSI)

    • Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024
    • Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024
    • Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024
    • Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions

    NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts.

    “We had an incredibly successful 2024, delivering double-digit growth in Royalty Receipts, which was significantly above our initial guidance, and deploying $2.8 billion of capital on value-enhancing royalties” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We are very excited for the opportunities ahead as the fundamentals of our business have never been stronger. Additionally, we have already taken two major steps at the start of 2025 to enhance shareholder value, announcing the acquisition of our external manager, which is expected to result in multiple financial and strategic benefits, and a new $3 billion share repurchase program, which highlights the confidence we have in our business and the attractive value we see in our shares. With a robust transaction pipeline and significant financial flexibility, I am confident that Royalty Pharma is well positioned to deliver attractive, compounding growth over the long term.”

    Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison

    • Royalty Receipts grew 12% to $729 million in the fourth quarter and 13% to $2,771 million for full year 2024, driven by strong performance from Evrysdi, the CF franchise, Trelegy, Tremfya and new royalty acquisitions.
    • Portfolio Receipts increased 1% to $742 million in the fourth quarter of 2024; Portfolio Receipts decreased 8% from $3,049 million to $2,801 million for full year 2024, largely reflecting $525 million in Biohaven-related milestone payments received in 2023.

    Capital Deployment of $2.8 billion in 2024 with royalties on eight new therapies added to the portfolio

    • Record year for synthetic royalty transactions for Royalty Pharma with $925 million announced in 2024.
    • Significantly expanded development-stage portfolio by acquiring royalties on four potential new therapies.

    Exciting new product launches expected across the royalty portfolio in 2025

    • Royalty Pharma to benefit in 2025 from new product launches, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s Rytelo.

    Financial guidance for full year 2025 (excludes contribution from future transactions)

    • Royalty Pharma expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to 9%.

    Financial & Liquidity Summary

      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
      (unaudited)
    ($ and shares in millions) 2024 2023 Change 2024 2023 Change
    Portfolio Receipts 742 736 1% 2,801 3,049 (8)%
    Net cash provided by operating activities 743 773 (4)% 2,769 2,988 (7)%
    Adjusted EBITDA (non-GAAP)* 669 682 (2)% 2,565 2,806 (9)%
    Portfolio Cash Flow (non-GAAP)* 678 687 (1)% 2,452 2,708 (9)%
    Weighted average Class A ordinary shares outstanding – diluted 589 598 (1)% 594 603 (1)%

    *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

    Portfolio Receipts Highlights

          Three Months Ended December 31,
          (unaudited)
    ($ in millions)     2024 2023 Change
    Products: Marketers: Therapeutic Area:      
    Cystic fibrosis franchise Vertex Rare disease 237 207 14%
    Trelegy GSK Respiratory 74 60 23%
    Tysabri Biogen Neuroscience 61 68 (11)%
    Evrysdi Roche Rare disease 56 20 182%
    Xtandi Pfizer, Astellas Cancer 46 38 20%
    Imbruvica AbbVie, J&J Cancer 46 50 (10)%
    Promacta Novartis Hematology 44 44 (1)%
    Tremfya Johnson & Johnson Immunology 39 35 11%
    Cabometyx/Cometriq Exelixis, Ipsen, Takeda Cancer 20 18 11%
    Spinraza Biogen Rare disease 15 17 (13)%
    Orladeyo BioCryst Rare disease 11 8 36%
    Trodelvy Gilead Cancer 11 10 10%
    Erleada Johnson & Johnson Cancer 11 9 25%
    Nurtec ODT/Zavzpret Pfizer Neuroscience 7 5 49%
    Other products(5) 54 63 (14)%
    Royalty Receipts 729 651 12%
    Milestones and other contractual receipts 13 84 (85)%
    Portfolio Receipts 742 736 1%

    Results for full year 2024 and 2023 are shown in Table 5. Amounts shown in the table may not add due to rounding.

    Royalty Receipts was $729 million in the fourth quarter of 2024, an increase of 12% as compared to $651 million in the fourth quarter of 2023. The increase was primarily driven by strong growth from Evrysdi, the cystic fibrosis franchise, Trelegy, Xtandi and Tremfya. Royalty receipts from Evrysdi included the benefit of the additional royalties acquired in October 2023 and June 2024.

    Portfolio Receipts was $742 million in the fourth quarter of 2024, an increase of 1% as compared to $736 million in the fourth quarter of 2023. The increase was primarily driven by the same Royalty Receipts increases noted above, offset by a decrease in milestones and other contractual receipts, which reflected a $50 million payment related to the oral formulation of zavegepant in the prior period.

    Liquidity and Capital Resources

    Royalty Pharma’s liquidity and capital resources are summarized below:

    As of December 31, 2024, Royalty Pharma had cash and cash equivalents of $929 million and total debt with principal value of $7.8 billion.

    During the fourth quarter of 2024, Royalty Pharma repurchased approximately two million Class A ordinary shares for $50 million. For full year 2024, Royalty Pharma repurchased approximately eight million Class A ordinary shares for $230 million. The weighted-average number of diluted Class A ordinary shares outstanding for the fourth quarter of 2024 was 589 million as compared to 598 million for the fourth quarter of 2023. The weighted-average number of diluted Class A ordinary shares outstanding for full year 2024 was 594 million as compared to 603 million for full year 2023.

    In January 2025, Royalty Pharma’s Board of Directors authorized a new share repurchase program under which Royalty Pharma may repurchase up to $3.0 billion of its Class A ordinary shares. Royalty Pharma intends to repurchase $2.0 billion of its shares in 2025, subject to market conditions. The total value of shares repurchased will depend on the discount to the intrinsic value at which its Class A ordinary shares are trading. This new share repurchase program replaces the unused $465 million of the company’s original $1.0 billion share repurchase program that was announced in March 2023.

    Liquidity Summary

      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
      (unaudited)
    ($ in millions) 2024   2023   2024   2023  
    Portfolio Receipts 742   736   2,801   3,049  
    Payments for operating and professional costs (72)   (54)   (236)   (243)  
    Adjusted EBITDA (non-GAAP) 669   682   2,565   2,806  
    Interest received/(paid), net 8   5   (113)   (98)  
    Portfolio Cash Flow (non-GAAP) 678   687   2,452   2,708  

    Amounts may not add due to rounding.

    • Adjusted EBITDA (non-GAAP) was $669 million in the fourth quarter of 2024. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.
    • Portfolio Cash Flow (non-GAAP) was $678 million in the fourth quarter of 2024. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

    Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

    Capital Deployment was $522 million in the fourth quarter of 2024, consisting primarily of the acquisitions of royalties on Niktimvo and Rytelo. Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $2.8 billion for full year 2024.

    The table below details Capital Deployment by category:

    Capital Deployment

      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
      (unaudited)
    ($ in millions) 2024   2023   2024   2023  
    Acquisitions of financial royalty assets (496)   (1,002)   (2,506)   (2,116)  
    Development-stage funding payments – upfront and milestone —   —   —   (50)  
    Development-stage funding payments – ongoing (1)   (1)   (2)   (2)  
    Purchases of available for sale debt securities —   —   (150)   —  
    Milestone payments (25)   —   (75)   (12)  
    Investments in equity method investees —   (2)   (11)   (13)  
    Acquisitions of other financial assets —   —   (18)   —  
    Contributions from legacy non-controlling interests – R&D 0   0   1   1  
    Capital Deployment (522)   (1,005)   (2,761)   (2,192)  

    Amounts may not add due to rounding.

    In January 2025, Royalty Pharma announced the sale of the MorphoSys Development Funding Bonds for $511 million in upfront cash (press release). This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The proceeds strengthen Royalty Pharma’s balance sheet and provide added flexibility to pursue its disciplined capital allocation strategy.

    Royalty Transactions

    For full year 2024, Royalty Pharma announced new transactions of up to approximately $2.8 billion. The announced transactions amount reflects the entire amount of capital committed for new transactions during the year, including potential future milestones.

    Recent transactions include:

    • In November 2024, Royalty Pharma acquired a synthetic royalty on Rytelo from Geron Corporation for an upfront payment of $125 million (press release). Rytelo is approved for the treatment of certain adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. Following the acquisition, Royalty Pharma is entitled to receive tiered royalties on U.S. net sales on Rytelo.
    • In November 2024, Royalty Pharma acquired a synthetic royalty on Niktimvo from Syndax Pharmaceuticals, Inc. for an upfront payment of $350 million (press release). Niktimvo is approved for the treatment of chronic graft-versus-host disease and will be co-commercialized by Incyte. Following the acquisition, Royalty Pharma is entitled to receive royalties on U.S. net sales on Niktimvo.

    The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

    Internalization Transaction

    In January 2025, Royalty Pharma agreed to acquire its external manager, RP Management, LLC (the “Manager”) (press release). This transaction to simplify Royalty Pharma’s corporate structure is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030 and driving cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity and simplifies Royalty Pharma’s corporate structure.

    The total transaction value of approximately $1.1 billion(7) consists of approximately 24.5 million shares of Royalty Pharma equity that will vest over five to nine years, approximately $100 million in cash(8), and the assumption of $380 million of the Manager’s existing debt.

    The closing of the internalization transaction is subject to shareholders’ approval of the issuance of the share consideration and other customary closing conditions, including required regulatory approvals. The transaction is estimated to close during the second quarter of 2025.

    Key Developments Relating to the Portfolio

    The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

    TEV-‘749 In January 2025, Teva announced that TEV-‘749 (olanzapine LAI) achieved Phase 3 targeted injections without PDSS (post-injection delirium/sedation syndrome), and the full safety presentation is expected in the second quarter of 2025.
    Cystic fibrosis franchise In December 2024, Vertex announced the U.S. Food and Drug Administration (FDA) approval of the new triple-combination modulator Alyftrek (vanzacaftor triple) for the treatment of cystic fibrosis in people ages 6 and older with at least one responsive mutation.

    In November 2024, Vertex announced that it had completed regulatory submissions for the vanzacaftor triple in the European Union, the United Kingdom, Canada, Australia, New Zealand and Switzerland, and reviews are underway.
    Skytrofa In December 2024, Ascendis announced the U.S. FDA accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency for Skytrofa. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.
    aficamten In December 2024, Cytokinetics announced that the FDA accepted its New Drug Application (NDA) for aficamten for the treatment of Obstructive Hypertrophic Cardiomyopathy. The FDA has assigned the NDA a Prescription Drug User Fee Act date of September 26, 2025. Additionally, the European Medicines Agency validated the Marketing Authorization Application for aficamten, and it will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).
    Trodelvy In November 2024, Gilead announced plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy for use in pre-treated adult patients with locally advanced or metastatic urothelial cancer, following the results of the Phase 3 TROPiCS-04 trial.
    Airsupra In October 2024, AstraZeneca announced that positive high-level results from the BATURA Phase 3b trial showed Airsupra met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol. These positive results triggered a milestone payment from AstraZeneca, of which Royalty Pharma received its pro rata portion of $27 million in January 2025.
    MK-8189 In October 2024, Merck updated its public disclosures to remove MK-8189 from its pipeline chart and Royalty Pharma does not anticipate making a further investment in this program.
    pelabresib In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in myelofibrosis. Novartis will continue to follow patients in MANIFEST-2 and evaluate the potential for additional studies to support registration.
    trontinemab In October 2024, Roche presented its latest Phase 1b/2a interim results for trontinemab at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, which demonstrated rapid and robust amyloid plaque depletion after 12 to 28 weeks of treatment and an overall favorable safety profile with very limited amyloid related imaging abnormalities (ARIA-E) observed.


    2025 Financial Outlook

    Royalty Pharma has provided guidance for full-year 2025, excluding new transactions and borrowings announced after the date of this release, as follows:

      Provided February 11, 2025
    Portfolio Receipts $2,900 million to $3,050 million
    (Growth of ~+4% to 9% year/year)
    Payments for operating and professional costs Approximately 10% of Portfolio Receipts(1)
    Interest paid $260 million

    The above Portfolio Receipts guidance represents expected growth of 4% to 9% in 2025. Royalty Pharma’s full-year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.

    2025 guidance for payments for operating and professional costs and interest paid does not reflect the impact of the internalization transaction announced on January 10, 2025 and will be updated following the closing of the internalization transaction, which is expected to be in the second quarter of 2025.

    Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately $260 million in 2025. Interest paid is anticipated to be approximately $138 million in the first quarter of 2025, which includes the first interest payment on the $1.5 billion notes issued in June 2024. Interest paid in the third quarter of 2025 is anticipated to be $119 million. De minimis amounts are anticipated in the second and fourth quarter of 2025. These projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility. In 2024, Royalty Pharma collected interest of $46 million on its cash and cash equivalents.

    Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

    Financial Results Call

    Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2024 results today at 8:30 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.

    Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

    This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

    Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

    For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Portfolio Receipts

    Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

    Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships. Distributions to RPSFT substantially ended in December 2023 when Royalty Pharma acquired the remaining interest in RPCT held by RPSFT.

    Use of Non-GAAP Measures

    Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP.

    Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

    The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

    Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

    The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6772
    ir@royaltypharma.com

     
    Royalty Pharma plc
    Condensed Consolidated Operations (unaudited)
    Table 1
     
      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
    ($ in millions) 2024   2023   2024   2023  
    Income and other revenues        
    Income from financial royalty assets 562   523   2,149   2,198  
    Other royalty income and revenues 32   73   114   157  
    Total income and other revenues 594   596   2,264   2,355  
    Operating expense/(income)        
    Provision for changes in expected cash flows from financial royalty assets 164   (77)   732   561  
    Research and development funding expense 1   1   2   52  
    General and administrative expenses 68   59   237   250  
    Total operating expense/(income), net 232   (17)   971   862  
    Operating income 362   613   1,292   1,492  
    Other (income)/expense        
    Equity in earnings of equity method investees (32)   (0)   (30)   (29)  
    Interest expense 66   47   226   187  
    Other income, net (7)   (152)   (234)   (366)  
    Total other expense/(income), net 27   (105)   (38)   (208)  
    Consolidated net income before tax 334   718   1,331   1,700  
    Income tax expense —   —   —   —  
    Consolidated net income 334   718   1,331   1,700  
    Net income attributable to non-controlling interests 126   223   472   565  
    Net income attributable to Royalty Pharma plc 208   494   859   1,135  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Selected Balance Sheet Data (unaudited)
    Table 2
     
    ($ in millions) As of December 31, 2024 As of December 31, 2023
    Cash and cash equivalents 929 477
    Total current and non-current financial royalty assets, net 15,911 14,827
    Total assets 18,223 16,382
    Current portion of long-term debt 998 —
    Long-term debt, net of current portion 6,615 6,135
    Total liabilities 7,880 6,298
    Total shareholders’ equity 10,342 10,084
     
    Royalty Pharma plc
    Consolidated Statements of Cash Flows (unaudited)
    Table 3
     
      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
    ($ in millions) 2024   2023   2024   2023  
    Cash flows from operating activities:        
    Cash collections from financial royalty assets 777   747   2,983   3,201  
    Cash collections from intangible royalty assets 0   0   15   1  
    Other royalty cash collections 30   75   109   159  
    Distributions from equity method investees —   —   13   19  
    Interest received 9   8   46   72  
    Development-stage funding payments – ongoing (1)   (1)   (2)   (2)  
    Development-stage funding payments – upfront and milestone —   —   —   (50)  
    Payments for operating and professional costs (72)   (54)   (236)   (243)  
    Interest paid (1)   (3)   (160)   (169)  
    Net cash provided by operating activities 743   773   2,769   2,988  
    Cash flows from investing activities:        
    Distributions from equity method investees 3   5   24   44  
    Investments in equity method investees —   (2)   (11)   (13)  
    Purchases of equity securities —   —   (63)   —  
    Proceeds from equity securities —   —   99   —  
    Purchases of available for sale debt securities —   —   (150)   —  
    Proceeds from available for sale debt securities 13   1   20   1  
    Proceeds from sales and maturities of marketable securities —   —   —   24  
    Acquisitions of financial royalty assets (496)   (1,002)   (2,506)   (2,116)  
    Acquisitions of other financial assets —   —   (18)   —  
    Milestone payments (25)   —   (75)   (12)  
    Other —   (2)   2   (2)  
    Net cash used in investing activities (506)   (1,000)   (2,678)   (2,073)  
    Cash flows from financing activities:        
    Distributions to legacy non-controlling interests – Portfolio Receipts (81)   (92)   (362)   (377)  
    Distributions to continuing non-controlling interests (31)   (24)   (125)   (120)  
    Dividends to shareholders (94)   (89)   (376)   (358)  
    Repurchases of Class A ordinary shares (53)   (30)   (230)   (305)  
    Contributions from legacy non-controlling interests – R&D 0   0   1   1  
    Contributions from non-controlling interests – other 1   1   4   7  
    Cash acquired in connection with purchase of non-controlling interest —   5   —   5  
    Proceeds from revolving credit facility —   350   —   350  
    Repayment of revolving credit facility —   (350)   —   (350)  
    Repayment of long-term debt —   —   —   (1,000)  
    Proceeds from issuance of long-term debt, net of discount —   —   1,471   —  
    Debt issuance costs and other 0   (2)   (13)   (2)  
    Other 0   —   (9)   —  
    Net cash (used in)/provided by financing activities (258)   (232)   361   (2,149)  
    Net change in cash and cash equivalents (21)   (459)   452   (1,234)  
    Cash and cash equivalents, beginning of period 950   936   477   1,711  
    Cash and cash equivalents, end of period 929   477   929   477  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    GAAP to Non-GAAP Reconciliation (unaudited)
    Table 4
     
      Three Months Ended
    December 31,    		 Twelve Months Ended
    December 31,
    ($ in millions) 2024   2023   2024   2023  
    Net cash provided by operating activities (GAAP) 743   773   2,769   2,988  
    Adjustments:        
    Proceeds from available for sale debt securities(6) 13   1   20   1  
    Distributions from equity method investees(6) 3   5   24   44  
    Interest (received)/paid, net(6) (8)   (5)   113   98  
    Development-stage funding payments – ongoing 1   1   2   2  
    Development-stage funding payments – upfront and milestone —   —   —   50  
    Distributions to legacy non-controlling interests – Portfolio Receipts(6) (81)   (92)   (362)   (377)  
    Adjusted EBITDA (non-GAAP) 669   682   2,565   2,806  
    Interest received/(paid), net(6) 8   5   (113)   (98)  
    Portfolio Cash Flow (non-GAAP) 678   687   2,452   2,708  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Fourth Quarter and Full Year Portfolio Receipts Highlights (unaudited)
    Table 5
     
      Three Months Ended December 31, Twelve Months Ended December 31,
    ($ in millions) 2024 2023 Change 2024 2023 Change
    Products:            
    Cystic fibrosis franchise 237 207 14% 857 771 11%
    Trelegy 74 60 23% 284 203 40%
    Tysabri 61 68 (11)% 262 279 (6)%
    Imbruvica 46 50 (10)% 191 210 (9)%
    Evrysdi 56 20 182% 174 66 163%
    Xtandi 46 38 20% 169 146 15%
    Promacta 44 44 (1)% 158 161 (2)%
    Tremfya 39 35 11% 140 116 20%
    Cabometyx/Cometriq 20 18 11% 73 66 10%
    Spinraza 15 17 (13)% 45 45 1%
    Trodelvy 11 10 10% 43 33 30%
    Erleada 11 9 25% 39 27 42%
    Orladeyo 11 8 36% 39 29 32%
    Nurtec ODT/Zavzpret 7 5 49% 26 18 39%
    Other products(5) 54 63 (14)% 273 277 (1)%
    Royalty Receipts 729 651 12% 2,771 2,449 13%
    Milestones and other contractual receipts 13 84 (85)% 31 599 (95)%
    Portfolio Receipts 742 736 1% 2,801 3,049 (8)%

    Amounts may not add due to rounding.

    Royalty Pharma plc
    Description of Approved Indications for Select Portfolio Therapies
    Table 6

    Cystic fibrosis franchise Cystic fibrosis
    Trelegy Chronic obstructive pulmonary disease and asthma
    Tysabri Relapsing forms of multiple sclerosis
    Evrysdi Spinal muscular atrophy
    Xtandi Prostate cancer
    Imbruvica Hematological malignancies and chronic graft versus host disease
    Promacta Chronic immune thrombocytopenia purpura and aplastic anemia
    Tremfya Plaque psoriasis, psoriatic arthritis and ulcerative colitis
    Cabometyx / Cometriq Kidney, liver and thyroid cancer
    Spinraza Spinal muscular atrophy
    Orladeyo Hereditary angioedema
    Trodelvy Breast and bladder cancer
    Erleada Prostate cancer
    Nurtec ODT/Zavzpret Acute and preventative treatment of migraine


    Notes

    (1)  Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that Royalty Pharma can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts include variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts and milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships. Distributions to RPSFT substantially ended in December 2023 when Royalty Pharma acquired the remaining interest in RPCT held by RPSFT.

    (2) Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

    (3) Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

    (4) Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments – ongoing, Development-stage funding payments – upfront and milestone less Contributions from legacy non-controlling interests – R&D.

    (5) Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Lexiscan, Nesina, Prevymis, Soliqua and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP statements of cash flows.

    (6) The table below shows the line item for each adjustment and the direct location for such line item on the GAAP statements of cash flows.

    Reconciling Adjustment Statements of Cash Flows Classification
    Interest received/paid, net Operating activities (Interest paid less Interest received)
    Distributions from equity method investees Investing activities
    Proceeds from available for sale debt securities Investing activities
    Distributions to legacy non-controlling interests – Portfolio Receipts Financing activities

    (7) The total transaction value of approximately $1.1 billion is based on the closing price of Royalty Pharma plc common stock of $26.20 on January 8, 2025.

    (8) Consists of $200 million in cash less the amount of the management fees paid to the Manager from January 1, 2025 through the closing of the transaction.

    The MIL Network –

  • MIL-OSI Asia-Pac: 45 Crore Devotees at Maha Kumbh 2025

    Source: Government of India (2)

    45 Crore Devotees at Maha Kumbh 2025

    Maha Kumbh 2025 Witnesses Record-Breaking Footfall

    Posted On: 11 FEB 2025 2:11PM by PIB Delhi

    The Maha Kumbh 2025 has become one of the largest religious gatherings in history, with over 450 million (45 crore) devotees participating in the bathing rituals as of February 11, 2025. The state government was expecting the number of devotees to reach 45 crore in 45 days but this number has already been achieved within one month, with 15 days still remaining for the Maha Kumbh to conclude. With its blend of spiritual significance, grand rituals, and cutting-edge technological interventions, this Kumbh Mela has set new benchmarks in crowd management, sanitation, and digital facilitation.

    With the number of visitors surpassing 45 crore, crowd management has been a major focus. The next Amrit Snan is on February 12, 2025, Magh Purnima Snan, which is renowned for its connection with the veneration of Guru Brahaspati and the belief that the Hindu deity Gandharva descends from the heavens to the sacred Sangam. To ensure smooth crowd management during the Magh Purnima Snan, the state government has designated the mela area as a ‘no vehicle zone’ from the morning of February 11, 2025, allowing only essential and emergency services.

    Indian Railways is also operating at full capacity to manage the Maha Kumbh 2025 crowd. On February 9, around 330 trains transported 12.5 lakh pilgrims, with 130 more departing by 3 PM on February 10. Preparations for the upcoming Amrit Snan on February 12, 2025 were reviewed by the officials and the Union Minister. All eight stations, including Prayagraj Junction, are fully operational, while Prayagraj Sangam station is temporarily closed around major bathing dates for crowd management.

    The state government, in collaboration with various agencies, implemented a multi-tier security and monitoring system. A network of AI-powered CCTV cameras, drone surveillance, and real-time analytics ensured the safe movement of pilgrims across designated sectors. The administration also introduced a digital token system to streamline access to bathing ghats, reducing overcrowding. Special provisions were made for senior citizens and differently-abled devotees, ensuring that the Kumbh remained an inclusive spiritual experience.

    Adding to the historical significance of Maha Kumbh 2025, the honourable President of India, Smt. Droupadi Murmu participated in the religious festivities on February 10, 2025. Her visit included a sacred dip at the Triveni Sangam, reinforcing the event’s spiritual importance at the highest levels of governance. The President also paid homage at key religious sites, and interacted with saints and devotees. Apart from President Murmu, several union ministers, chief ministers, and governors, including Prime Minister Narendra Modi, Home Minister Amit Shah, Defence Minister Rajnath Singh have also taken a holy dip in the Sangam. Celebrities from Bollywood and the Indian sports fraternity have also marked their presence, engaging in religious rituals and public interactions. The participation of revered saints and spiritual leaders has further amplified the sanctity and grandeur of the event.

       

    Kalpavas, a period of fasting and spiritual discipline, holds deep significance during Maha Kumbh. This year, over 10 lakh devotees observed Kalpavas at the Triveni Sangam, concluding on Magh Purnima, with a final holy dip, pujan, and daan. As per tradition, Kalpvasis will perform Satyanarayan Katha, Havan Puja, and offer donations to their Tirthpurohits. The barley sown at the start of Kalpavas is immersed in the Ganga, and the Tulsi plant is taken home as a divine blessing. The twelve-year Kalpavas cycle culminates in Maha Kumbh, followed by a community feast in their villages.

    Over 7 lakh pilgrims have received medical care through extensive healthcare services. This includes treatment of more than 4.5 lakh individuals at 23 allopathic hospitals, with over 3.71 lakh undergoing pathology tests, and the successful completion of 3,800 minor and 12 major surgeries. Additionally, 20 AYUSH hospitals have provided Ayurveda, Homeopathy, and Naturopathy treatments to over 2.18 lakh pilgrims. The integration of specialists from AIIMS Delhi, IMS BHU, and international experts from Canada, Germany, and Russia has ensured world-class healthcare. Services such as Panchakarma, yoga therapy, and the distribution of health awareness materials have been well-received, enhancing the overall well-being of attendees.

    Aiming to make this the cleanest Kumbh Mela ever, authorities have enforced a stringent waste management plan. Over 22,000 sanitation workers have been deployed, ensuring that the premises remain free of litter. A large-scale water treatment initiative has also been implemented to keep the river water clean and suitable for the sacred dips. Eco-friendly practices, such as banning plastic and using biodegradable cutlery, have been strictly enforced. The Swachh Bharat Mission’s influence is evident in the installation of thousands of bio-toilets and automated garbage disposal units across the Kumbh grounds.

    Throughout the event, cultural programs featuring classical dance performances, folk music, and spiritual discourses take center stage, captivating devotees and visitors alike. Renowned artists, including Padma awardees and folk troupes from various states, showcase the diverse traditions of India through Kathak, Bharatanatyam, and traditional folk dances like Lavani and Bihu. The Kumbh Mela is also hosting various literary gatherings, where scholars discuss ancient scriptures, Vedic philosophy, and the relevance of Sanatan Dharma in contemporary times. Artisans set up stalls displaying handicrafts, handloom products, and religious artifacts, turning the mela into a vibrant cultural confluence.

    Maha Kumbh 2025 is not just a religious gathering; it is a monumental example of meticulous planning, cultural preservation, and technological innovation. With over 45 crore devotees already participating and more expected before its conclusion, this Kumbh stands as a testament to India’s ability to blend tradition with modernity, ensuring a spiritually enriching and seamless experience for all.

    References

    Department of Information & Public Relations (DPIR), Government of Uttar Pradesh

    https://kumbh.gov.in/en/bathingdates

    Maha Kumbh Series: 23/Feature

    Click here to see PDF.

    ******

    Santosh Kumar | Sarla Meena | Rishita Aggarwal

    (Release ID: 2101679) Visitor Counter : 83

    MIL OSI Asia Pacific News –

  • MIL-OSI Security: Commissioner – law ruling leaves policing in a “hopeless position”

    Source: United Kingdom London Metropolitan Police

    The Commissioner has responded to a High Court judgment published today on a judicial review that sought to challenge Operation Assure.

    Operation Assure is the Met’s process, based on national guidance, to consider dismissing officers who can no longer pass vetting. The Met lost the judicial review.

    Commissioner Sir Mark Rowley said:

    “For more than two decades police leaders have been asking Government for greater powers to sack officers who are not fit to wear the uniform. For two-and-a half-years I have repeated that call and successive Governments have promised change.

    “Tens of thousands of good officers joined the police because we care deeply about public safety. The majority of the Met is committed to this drive to clear out those who threaten our collective integrity. This makes us better placed to protect communities.

    “Being able to sack officers who fail vetting is critical. Under Op Assure, in the last 18 months

    • 96 officers have been sacked or resigned due to vetting removal
    • 29 more are on special vetting leave, having lost vetting
    • Over 100 more are in the early stages of vetting reviews

    “Those we have removed vetting from, had a pattern of behaviour that meant if they applied to work in policing today, we’d never let them in.

    “But today’s ruling on the law has left policing in a hopeless position.

    “We now have no mechanism to rid the Met of officers who are not fit to hold vetting – those who cannot be trusted to work with women, or enter the homes of vulnerable people.

    “It is absurd that we cannot lawfully sack them – this would not be the case in other sectors where staff have nothing comparable to the powers a police officer holds.

    “This judgement is focussed on the human rights of Sgt Di Maria. But there are wider human rights at play here, those of the public, and those of colleagues who have to work alongside officers like this.

    “We are seeking leave to appeal the judgment, not just for the Met but for law enforcement nationally due to these profoundly damaging implications.

    “The judge identified a clear gap in the law, one we have done our best to bridge. But as the judge said, the answer lies in strengthened Police Vetting Regulations.

    “So in repeating the same request for two-and-a half-years, echoed by the Casey and Angiolini reports, I am once again calling on the Government today, to introduce new regulations as a matter of extreme urgency.

    “It is crucial they are practical, nimble and empowering. They must allow police forces to deal with those who pose risks to colleagues and of course to the public, and must apply to those we have already removed.

    “Finally, regardless of the current legal framework, the public of London have my assurance and that of my colleagues that Di Maria and those like him will not be policing the streets or working alongside other officers. They will remain on ‘vetting special leave’, a ridiculous waste of public money but the least bad option until regulations are fixed. “

    +++

    A judgment has been published in relation to a judicial review heard at the High Court between 15 and 16 January 2025.

    Sgt Lino Di Maria is a Met officer who during his police service has received allegations of rape, and other allegations about his conduct towards women.

    Under the Met’s ‘Operation Assure’ – a key part of our drive to raise standards and root out corruption – Di Maria’s vetting clearance was reviewed and, in light of the significant pattern of adverse information against him, his vetting was removed.

    Sgt Di Maria applied to the court for judicial review, challenging the lawfulness of the Met’s decision to remove his vetting and refer him to gross incompetence proceedings.

    He challenged the wider Operation Assure process which is the Met’s process, based on national guidance, to consider dismissing officers who can no longer pass vetting.

    The officer would have been dismissed many months ago but for this legal action, which is funded in support of him by the Police Federation.

    The College of Policing and Home Secretary were interested parties to the proceedings.

    The judgment has found in favour of Sgt Di Maria. It is published here: Di Maria -v- Met Police and others – Courts and Tribunals Judiciary

    Background

    Operation Assure

    In March 2023 the Met became the first police service in the UK to adopt a new process, based on College of Policing guidance and called Operation Assure, to consider dismissing officers and staff who can no longer pass vetting.

    It is unacceptable there has never been an explicit legal provision to enable sacking of officers who fail vetting reviews. Policing has asked for this loophole to be closed for more than 20 years. We have been promised for two-and-a-half years that changes will happen but little progress has been made.

    The regulations make it too hard to remove those few who undermine the majority. Our own analysis and that of Casey and Angiolini pointed to the need to ‘join the dots’ – using intelligence to spot patterns of behaviour to remove those who should not be in the job. This followed in the wake of significant cases such as Wayne Couzens and David Carrick.

    Operation Assure is a programme of prioritised vetting reviews for serving officers and staff where we hold significant adverse information that means we need to review their vetting clearance. In most cases this information has not previously led to a criminal conviction, and, in all cases, not dismissal from the Met.    

    Operation Assure provides a pathway for the Met to follow if an officer’s basic vetting clearance cannot be maintained. It can lead to that person being dismissed from the Met at a gross incompetence hearing – as their inability to hold vetting clearance makes them ‘incompetent’ to hold a role.

    There are hundreds of pages of guidance, law and regulations telling us at length how important vetting is and how it should be done. But these are far less clear on what to do if things change and an officer can no longer can be trusted to hold that vetting, nor how such an officer should be dismissed.

    We carefully interpreted the existing guidance and laws as best we could and we filled that gap in the public interest. Operation Assure was the right thing to do in circumstances when the law did not provide a clear way of doing this, and it was supported by the College of Policing. It was a risk, but the issue was too important to ignore and too urgent to wait – the public deserve better.

    Police officers are vetted when they join the Met, with vetting renewal every seven-10 years. The framework exists in the Vetting Approved Professional Practice – as set by the College of Policing.  The framework also says that vetting clearance should be reviewed upon ‘adverse information’.

    The majority of those subject to Assure have worrying patterns of behaviour, mainly allegations of sexual offending. They would not pass vetting if joining the police for the first time today.

    The primary pipeline for Operation Assure is Operation Onyx. The Operation Onyx team have reviewed completed domestic or sexual abuse cases against officers and staff for offences from the last 10 years (until April 2022) to ensure those cases were dealt with properly, and revisit them if not via Operation Assure.

    Operation Assure to date

    • More 300 officers and staff referred into the Assure process overall so far.
    • 107 officers/staff have had vetting withdrawn. 
    • 96 officers/staff have exited the Met (dismissals, retirements and resignations) while in the Op Assure process (including 19 who resigned before their gross incompetence hearing). 
    • This includes 24 officers/staff dismissed at gross incompetence hearing (or staff equivalent) for failure to maintain vetting.
    • Today, 29 officers and staff are in the Met having had their vetting removed and are on vetting special leave. Until the judgment today, 12 of those were due to attend a hearing soon where they may have been dismissed – others had appeals ongoing.
    • Approximately 100 officers and staff are at an earlier stage of the Assure process – perhaps at an early review stage, or awaiting their vetting interview or vetting decision.

    And:

    • 82 have had their vetting retained – which is important to note as it shows the process is fair and proportionate.
    • 7 successful appeals. 

    Examples

    • Officer received multiple rape and sexual assault allegations from a number of separate female complainants in 2011-2023. Under Op Assure, officer had vetting reviewed, removed and he was dismissed at a gross incompetence hearing. Criminal charges followed a year later, as further information came to light following his dismissal. This was the first officer we dismissed under Assure, in October 2023.
    • Officer had numerous domestic abuse allegations, including rape of ex-partner, and also had received two reports of sexual assault/harassment of colleagues. He had been reduced in rank to a PC in 2022 for a separate matter for misuse of his warrant card while off-duty. Under Op Assure, officer had vetting reviewed, removed and he was dismissed at a gross incompetence hearing.     
    • Officer committed indecent act on a train and pleaded guilty to outraging public decency – later received a final written warning. Under Op Assure, officer had vetting reviewed, removed and he was dismissed at a gross incompetence hearing. 
    • Following intelligence checks it was identified that a serving officer was arrested in the USA on charge of endangering welfare of child, having travelled there to meet a 13-year-old girl he had met online.  No criminal charges were brought but the intelligence was reconsidered as part of Assure. Officer resigned in May 2023 when he was told he was to have a vetting review.

    Judicial Review

    A Judicial Review took place at the High Court on 15/16 January between Met officer Sgt Lino Di Maria, supported by the Met Police Federation, and the Met Police supported by the College of Policing and the Home Office as interested parties.

    The Judicial Review challenged the legality of Operation Assure, and how it applied to Sgt Di Maria’s case.

    The multiple historic and serious allegations against Sgt Lina Di Maria, attached to forensics at Kentish Town, were outlined in the hearing.

    His vetting clearance was removed in Sept 2023 and his appeal against this dismissed. In March 2024 he was referred to a gross incompetence hearing due to having no vetting clearance. His particular case was paused pending the outcome of the JR.   

    MIL Security OSI –

  • MIL-OSI: ThreeD Capital Inc. Provides Update on TODAQ Investment

    Source: GlobeNewswire (MIL-OSI)

    TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to congratulate TODAQ Micro Inc. (“TODAQ Micro”) on the successful commercialization of its technology.

    ThreeD is an investor in TODAQ Micro. Additionally, ThreeD owns 478,739 preferred shares in TODAQ Holdings Inc. (“TODAQ Holdings”), the parent company of TODAQ Micro, as well as owning five TODA Note Royalty Certificates (“TDN Royalties”) with an aggregate maximum value of USD$279,613,283. Each TDN Royalty entitles the holder to receive royalty payments over time to the holder’s micropayment node, subject to certain terms and conditions. Each TDN has been fixed at $USD 1 per TDN by TODAQ Holdings.

    TODAQ Micro is now releasing its groundbreaking TAPPTM micropayments solution to address long-standing inefficiencies in the digital economy.

    The company’s first commercial deployment is in the entertainment industry, where TODAQ Micro is enabling a revolutionary “fair trade Netflix” experience with a new video platform called Truce Plus (‘Truce+’). Producers, studios and distributors that own Tier 1 movie, show, and documentaries face multiple headwinds trying to sell to the leading content platforms. These challenges include poor negotiating power, loss of relationship with the viewing customer, low upfront payments and poor revenue share terms, delayed payments, and limited transparency and recourse to name just a few. By embedding micropayments into Truce+ digital content transactions, TODAQ Micro enables these content owners to go directly to consumer (DTC) with a frictionless, real-time, pay as you go model that also enables users to instantly buy and rent content in a few seconds without needing to subscribe or login. The content producers are paid in real time and can also instantly micro distribute those revenues to cast, crew and other supply chain payees eliminating nearly all back office costs. The first commercial movie powered by TAPP will be available in February and is called the Flamingo Effect and is produced by Truce Studios in Denver, CO. The first half dozen content titles that include both American and Canadian Tier 1 producers of movies and TV shows will be available in Q1 with over 100 titles being put on the platform by the end of the year. The Truce+ platform can also provide instant referral bonuses and awards to studios and viewers that bring in additional followers. Fortune Business Insights values the global video streaming market size at USD 674 billion in 2024 with growth to USD 2,661 billion by 2032, exhibiting a CAGR of 18.7% during the forecast period, driven by Increasing Demand for Video on Demand (VoD) streaming services.

    “There are almost too many places TAPP can be applied. Given the massive size and growth rate of the streaming industry it was a natural first place to focus. In addition, the market pain felt by the subscription fatigued consumer and the content producers who feel that they are not getting a fair deal means we have a unique ability to make the market much better and larger for both parties. TAPP represents the only deeptech powered platform capable of enabling full microtransaction VoD (or MVoD) as a new streaming market category,” said Hassan Khan, CEO of TODAQ Micro.

    TODAQ Micro has garnered significant recognition, recently being named a Top 8 FinTech Startup by the Government of Canada and sent to Silicon Valley as part of the Canadian Technology Accelerator Program with the Canadian Consulate in San Francisco. The company boasts strong strategic partnerships and finalized a partnership with Oracle in the summer of 2024 to ensure it has massive capacity to scale, and to provide the streaming industry with micropayable data labelling for video content and AI conversational agents that can close movie sales, take payments, and initiate micro-distributions. TODAQ Micro has deployed its technology on Oracle Cloud Infrastructure (OCI) and successfully demonstrated multi-cloud transactions between OCI and Amazon AWS without reliance on traditional payment processors or blockchain networks. This innovation enables businesses to monetize micro-services without locking customers into subscriptions, providing a cost-efficient, pay-as-you-go alternative.

    Traditionally, enabling secure, private online web payments with a 5 second checkout for a consumer have not been possible and micro-payments of less than a dollar are impractical due to high processing costs. TODAQ’s technology eliminates intermediaries, enabling seamless transactions for businesses and consumers alike. Rather than using a blockchain, TODAQ solved the problem by returning to the original architecture of the World Wide Web and added a new Web Application Protocol called ADOT to coexist alongside HTTPS, SMTP and other older protocols built to handle websites, emails and other data. TODAQ also added another cryptographic technology called TODA to ensure portable integrity for these new web asset transactions. Together TODA and ADOT enable any software system to create, update, verify and transfer unique digital assets without requiring payment and authentication rails, or blockchains. This project took over six years, and involved collaboration with Cambridge University researchers at the Cambridge Centre for Redecentralization (CRDC) and support from the UK Research and Innovation Ministry alongside private investment. TAPP is the first ADOT Web native commercial application created.

    Sheldon Inwentash, Chairman and Chief Executive Officer of ThreeD, commented: “TODAQ Micro has made tremendous advancements, achieving major milestones with the commercialization of its technology and attracting tier one strategic partners. It has emerged as a leader in providing micropayment solutions without the high costs traditionally associated with such transactions. We are very pleased to have been an early-stage investor in TODAQ and look forward to seeing the company continue to scale and disrupt the industry.”

    More information about TODAQ Micro can be found through the ThreeD YouTube channel where Hassan Khan, CEO of TODAQ Micro, is interviewed.

    About ThreeD Capital Inc.

    ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.

    For further information:

    Jakson Inwentash
    Vice President Investments
    jinwentash@threedcap.com
    Phone: 416-941-8900 ext 107

    The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

    Forward-Looking Statements

    This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Often, but not always, these forward looking statements can be identified by the use of words such as “believe”, “believes”, “estimate”, “estimates”, “estimated”, “potential”, “open”, “future”, “assumed”, “projected”, “used”, “detailed”, “has been”, “gain”, “upgraded”, “offset”, “limited”, “contained”, “reflecting”, “containing”, “remaining”, “to be”, “periodically”, or statements that events, “could” or “should” occur or be achieved and similar expressions, including negative variations.

    Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes the expectations reflected in these forward-looking statements are reasonable, there can be no assurance they will prove accurate. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

    The MIL Network –

  • MIL-OSI: Thriving and Flourishing Throughout 2024, Plum Sets Sights on Continued Growth in 2025

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) — Reflecting on the company’s 18 percent growth over the past year, revolutionary talent assessment provider Plum expects to see the trend accelerate in the coming months. Citing the versatility of its offerings across the employee journey, including talent acquisition, internal mobility and leadership development, Plum secured several new clients, expanded existing relationships and forged significant partnerships throughout 2024.

    Plum CEO Caitlin MacGregor commented, “For Plum, 2024 was marked by the launch of PlumFlourish and PlumThrive, which were driven by the need to address very specific workforce challenges around career development and talent insights. Because of this, Plum is able to ensure that employees and employers can navigate today’s dynamic business environment, and enterprise organizations are looking to us for that guidance.”

    With the availability of PlumFlourish and PlumThrive alongside the company’s other enterprise solutions, Plum began working with Advocate Aurora Health, Scotia Caribbean and Temenos while expanding relationships with a Canadian multinational investment bank and financial services company, Arup, Bloomberg, CMP, Foundever and Hyundai Canada. Through Plum’s continued support for its customer base, the company helped to reimagine hiring processes, improve productivity, fill positions with internal talent, promote team development, maximize team efficiency and allow human potential to drive decision-making.

    On the partnership front, Plum added FairNow, Fountain, HackerRank, North Star Talent and Paylocity to its marketplace and finalized integration experiences with iCIMS and Paylocity. Plum also expanded its partnership with SAP SuccessFactors.

    MacGregor concluded, “By focusing on product and nurturing our relationships, Plum has built a strong foundation and maintained momentum, even through the headwinds observed last year. That’s what sets Plum apart and what makes Plum poised for success in 2025.”

    About Plum

    Revolutionary workforce solutions provider Plum knows that when people flourish, business thrives. Using objective data backed by scientific insights to measure and match human potential to job needs, Plum provides personalized career insights, improves quality of hire and helps create high-performing teams.

    With unmatched scalability, the award-winning Plum platform enhances talent decisions across the employee lifecycle, making it possible to understand skills, quantify job fit and analyze organizational culture. Visit www.plum.io to learn more.

    The MIL Network –

  • MIL-OSI: Anterix Announces Industry Engagement Initiative to Accelerate Private Wireless Broadband Opportunity and Engages Morgan Stanley to Initiate Strategic Review Process

    Source: GlobeNewswire (MIL-OSI)

    WOODLAND PARK, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) — Anterix (NASDAQ: ATEX) announced today that after receiving inbound interest in the Company, it has engaged Morgan Stanley & Co. LLC (“Morgan Stanley”) as its financial advisor to support a formal strategic review process for the Company to capitalize on the growing demand and urgency for private wireless broadband solutions for the utility industry.

    Additionally, as the recognized market leader in the private wireless broadband space for utilities, Anterix has launched a new industry engagement initiative to address and shorten the time to realization of value for Anterix and its customers to allow them to more quickly deploy 900 MHz private wireless broadband networks. This initiative, which will include a significant review of pricing, payment and ownership terms as well as the potential for collaboration with strategic partners on additional products and services with Anterix’s 120+ member ecosystem, is already receiving significant interest from utilities.

    “Anterix has more experience regarding how to enable private networks for utilities than anyone. With this new initiative, we are going to aggressively evolve our product offering to build on that success. With our seven customers across fifteen states, our 120+ member ecosystem, and our fantastic team, we are poised to continue to capture the growing utility wireless broadband marketplace,” said Scott Lang, President & CEO of Anterix.

    Mr. Lang continued, “As the leading provider of private wireless broadband, zero debt, and a strong customer pipeline, it does not surprise us that we have had some inbound strategic interest to participate with us in our efforts. Accordingly, we have turned to the leaders in this field, Morgan Stanley. With them, we will review strategic opportunities to capitalize on the value that lies in front of us, with a focus on what is in the best interest of our shareholders, customers and employees. I am excited to work with Morgan Stanley on this strategic review and equally excited to see the extensive utility interest in the evolution of our product offering.”

    As a reminder, Anterix previously announced that it will be hosting its third quarter fiscal 2025 earnings call tomorrow, Wednesday February 12, 2025, at 9:00 A.M. ET. More information can be found on the Investor Relations section of Anterix’s website at https://investors.anterix.com/events-presentations.

    There is no deadline or definitive timetable for completion of the strategic review, and there can be no assurance regarding the results or the outcome of this review. Anterix does not intend to make any further announcements regarding the strategic review except in accordance with its ongoing disclosure obligations and pursuant to applicable laws and regulations.

    Shareholder Contact 

    Natasha Vecchiarelli
    Vice President, Investor Relations & Corporate Communications
    Anterix
    973-531-4397
    nvecchiarelli@anterix.com 

    About Anterix

    At Anterix, we partner with leading utilities and technology companies to harness the power of 900 MHz broadband for modernized grid solutions. Leading an ecosystem of more than 100 members, we offer utility-first solutions to modernize the grid and solve the challenges that utilities are facing today. As the largest holder of licensed spectrum in the 900 MHz band (896-901/935-940 MHz) throughout the contiguous United States, plus Alaska, Hawaii, and Puerto Rico, we are uniquely positioned to enable private wireless broadband solutions that support cutting-edge advanced communications capabilities for a cleaner, safer, and more secure energy future. To learn more and join the 900 MHz movement, please visit www.anterix.com.

    Forward-Looking Statements

    Certain statements contained in this press release constitute forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future events or achievements such as statements in this press release related to Anterix’s industry engagement initiatives or strategic review or business or financial results or outlook. Actual events or results may differ materially from those contemplated in this press release. Forward-looking statements speak only as of the date they are made and readers are cautioned not to put undue reliance on such statements, as they are subject to a number of risks and uncertainties that could cause Anterix’s actual future results to differ materially from results indicated in the forward-looking statement. Such statements are based on assumptions that could cause actual results to differ materially from those in the forward-looking statements, including: (i) the timing of payments under customer agreements; (ii) Anterix’s ability to clear the 900 MHz Broadband Spectrum on a timely basis and on commercially reasonable terms; (iii) Anterix’s ability to qualify for and timely secure broadband licenses; (iv) Anterix’s ability to execute on its industry engagement initiatives; (v) the timing and outcome of Anterix’s strategic review process; (vi) whether Anterix will be able to identify, develop or execute on any actions as a result of its strategic review process and (vii) competition in the market for spectrum and spectrum solutions offered by Anterix. Actual events or results may differ materially from those contemplated in this press release. Anterix’s filings with the Securities and Exchange Commission (“SEC”), which you may obtain for free at the SEC’s website at http://www.sec.gov, discuss some of the important risk factors that may affect the Company’s financial outlook, business, results of operations and financial condition. Anterix undertakes no obligation to update publicly or revise any forward-looking statements contained herein.

    The MIL Network –

  • MIL-OSI Video: Secretary Wright joins FOX’s Will Cain – February 10th, 2025

    Source: United States of America – Federal Government Departments (video statements)

    https://www.youtube.com/watch?v=2VpOcNPlRmY

    MIL OSI Video –

  • MIL-OSI Video: Artemis II to the Moon: Launch to Splashdown (NASA Mission Animation)

    Source: United States of America – Federal Government Departments (video statements)

    The Artemis II mission, slated to launch early 2026, will fly four astronauts around the Moon. This mission will last for about 10 days and will be the first crewed test flight of the Space Launch System rocket, the Orion spacecraft, and the Exploration Ground Systems at NASA’s Kennedy Space Center Florida needed to support them.

    Not only will this mission be the first time in over 50 years that human beings have seen the Moon close-up, Artemis II will also prepare us for future human landings on the Moon starting with the Artemis III mission and help prepare for future missions to Mars.

    To learn more about the Artemis II mission, visit: https://www.nasa.gov/mission/artemis-ii/

    Credit: NASA

    https://www.youtube.com/watch?v=Ke6XX8FHOHM

    MIL OSI Video –

  • MIL-OSI Video: Homeland Security Committed to Safe Super Bowl

    Source: United States of America – Federal Government Departments (video statements)

    Department of Homeland Security Secretary Kristi Noem talks about DHS’s commitment to a safe Super Bowl.

    https://www.youtube.com/watch?v=GAbmjLJnUzc

    MIL OSI Video –

  • MIL-OSI USA: NIH study finds infection-related hospitalizations linked to increased risk of heart failure

    Source: US Department of Health and Human Services – 2

    News Release

    Tuesday, February 11, 2025

    Findings highlight the importance of infection prevention measures and personalized heart failure care.

    A study funded by the National Institutes of Health has found that adults who were hospitalized for a severe infection, such as respiratory infections or sepsis, were more than twice as likely to develop heart failure years later. The findings, published in the Journal of the American Heart Association, underscore the importance of measures that help prevent severe infections, such as getting up-to-date vaccines and practicing safe hygiene.

    “These are ‘sit-up and take notice’ findings,” said Sean Coady, M.A., deputy branch chief in the Division of Cardiovascular Sciences at the NIH’s National Heart, Lung, and Blood Institute. “While there’s already a reasonable body of evidence linking previous infections with heart attack, this study is focused on heart failure, which has been less studied yet affects an estimated six million Americans.”

    The study, part of the NHLBI-funded Atherosclerosis Risk in Communities (ARIC) Study, followed 14,468 adults aged 45-64 for up to 31 years, from 1987 to 2018. None had heart failure when the study began. The researchers found that individuals who experienced an infection-related hospitalization had a 2.35 times higher risk of developing heart failure at an average time of seven years after surviving the hospitalization, compared to those who did not get an infection. The researchers adjusted for sociodemographic and health-related factors and included different infection types, such as respiratory, urinary tract infections, and hospital-acquired in their assessment. They found that the association with heart failure was consistent no matter the type of infection.

    Heart failure occurs when the heart is unable to pump enough blood to the body’s organs and tissues. While there are many different kinds, the study focused mainly on heart failure with preserved ejection fraction (HFpEF), which occurs when the left side of the heart is too stiff to fully relax between heartbeats, and heart failure with reduced ejection fraction (HFrEF), which occurs when the left ventricle is too weak to pump out enough blood to the body. The researchers discovered that infections that required hospitalization were associated with an increased risk of both conditions. Notably, the risk was nearly three times higher for HFpEF, the most common form of heart failure among people over age 65 and the one with the most limited treatment options. Nearly half of participants experienced an infection-related hospitalization emphasizing the potentially large impact of severe infections on the heart health of older adults.

    While the study only found an association between severe infections and heart failure – not a causal link – Ryan Demmer, Ph.D. professor of epidemiology at the Mayo Clinic in Rochester, Minn. and the study’s senior author, said patients still should consider commonsense approaches that keep severe infections at bay. He explained that someone who experiences an infection and are at high risk for cardiovascular disease should speak with their primary care provider to be sure they are receiving guideline directed medical therapies for cardiovascular disease.

    Demmer said future research could build on the current findings by validating a causal link between infections and heart failure development. New research could also explore the potential for incorporating infection history into heart failure risk assessments and patient management strategies.

    About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

    About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH…Turning Discovery Into Health®

    Reference

    Molinsky RL, Shah A, Yuzefpolskaya M. Infection-Related Hospitalization and Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. Journal of the American Heart Association. 2025. DOI: 10.1161/JAHA.123.033877R

    ###

    MIL OSI USA News –

  • MIL-OSI USA: Single dose of broadly neutralizing antibody protects macaques from H5N1 influenza

    Source: US Department of Health and Human Services – 2

    Media Advisory

    Tuesday, February 11, 2025

    NIH science lays groundwork for future studies in people.

    What

    National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from severe H5N1 avian influenza. Highly pathogenic avian influenza (HPAI) H5N1 viruses have sporadically spilled over from birds into many other animals, including humans and dairy cows, in recent years. Although it has not yet acquired the capacity to spread readily between people, H5N1 has pandemic potential, which has spurred efforts to develop effective treatments and other countermeasures.

    The investigators studied a bnAb called MEDI8852, which was discovered and developed by Medimmune, now part of AstraZeneca. MEDI8852 targets a portion of a key flu protein that is less prone to change than other parts of the virus and thus is capable of conferring protection against a wide range of flu viruses. In the new study, a group of macaques received an injection of MEDI8852 and were exposed to aerosolized HPAI H5N1 virus three days later. All the pre-treated animals survived and experienced no or very limited signs of disease. In contrast, a group of control macaques developed severe or fatal illness within a short time after virus exposure. Of note, the scientists determined that MEDI8852 remained in the body for a prolonged time after the injection. According to scientists, protection from severe disease would extend to weeks beyond antibody infusion, providing a realistic preventative window in the face of an H5N1 outbreak.

    The research was conducted by Masaru Kanekiyo, D.V.M, Ph.D., and colleagues from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) along with investigators from the University of Pittsburgh. It was published in Science.

    Article

    M Kanekiyo et al. Pre-exposure antibody prophylaxis protects macaques from severe influenza. Science DOI: 10.1126/science.ado6481 (2025).

    Who

    Dr. Kanekiyo, VRC, NIAID, is available to comment.

    This research was supported by the Vaccine Research Center, NIAID, NIH, as well as grants R01AI154894 and UC7AI180311 and contracts 75N93021C00014 and HHSN261201500003.

    NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

    About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH…Turning Discovery Into Health®

    ###

    MIL OSI USA News –

  • MIL-OSI USA: NIH-funded clinical trial will evaluate new dengue therapeutic

    Source: US Department of Health and Human Services – 2

    News Release

    Tuesday, February 11, 2025

    A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease. The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and will involve exposing adult volunteers to a weakened strain of dengue virus that causes a mild form of the disease and administering an investigational therapeutic at various doses to assess its safety and ability to lessen symptoms.

    Dengue is transmitted via infected Aedes mosquitoes and sickens as many as 400 million people each year, primarily in tropical and subtropical parts of the world, according to the U.S. Centers for Disease Control and Prevention. In 2024, dengue cases surged to record levels in the Americas with local U.S. transmission reported in Arizona, California, Florida, Hawaii, and Texas. Dengue is endemic in Puerto Rico, which reported nearly 1,500 cases last year. Most people with dengue do not develop symptoms, but those who do commonly experience severe headache and body aches, nausea and vomiting, fever and rash. One in 20 people who get sick with dengue progress to severe illness, which may lead to shock, internal bleeding, and death. There is currently no Food and Drug Administration-approved treatment for dengue.

    “When caring for a patient who is critically ill with dengue, healthcare providers have few options other than providing supportive care,” said NIAID Director Jeanne Marrazzo, M.D., M.P.H. “We must find safe and effective therapeutics to provide much-needed relief to people suffering from dengue.”

    The new clinical trial will test the ability of AV-1, an investigational human monoclonal antibody therapeutic developed by AbViro (Bethesda, Maryland), to mitigate clinical symptoms when administered before and after dengue virus infection. The results of a previously completed NIAID-supported Phase 1 trial indicated that AV-1 is safe in humans, providing the basis for the new clinical trial to test its safety and efficacy.

    The Phase 2 clinical trial will enroll at least 84 healthy adult volunteers at two sites: the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, and the University of Vermont Vaccine Testing Center in Burlington. Following an initial screening and physical examination, volunteers will be randomly assigned to one of two groups. One group will receive AV-1 one day prior to being challenged with a mild strain of dengue virus, and the other will receive AV-1 four days after being challenged with the dengue virus. Each group will be further subdivided to receive 100 mg, 300 mg, or 900 mg of AV-1, delivered in a 60-minute intravenous infusion. For each of the three dosage levels, 12 participants will receive the investigational monoclonal antibody, and two will receive a placebo.

    Before or after AV-1 dosing, each volunteer will receive an injection of attenuated (weakened) dengue virus. In earlier studies using this challenge virus, most volunteers developed a rash, and some had other mild dengue symptoms, such as joint and muscle pain or headache. None of the volunteers developed dengue fever or severe dengue.

    Volunteers will participate in regular follow-up visits with study staff for at least 155 days to carefully monitor the effects of the investigational monoclonal antibody. Through physical exams, diary cards and blood samples, researchers will document how the volunteers’ immune systems respond to the dengue virus challenge, how quickly the virus vanishes from their bloodstream and any symptoms they may experience. The researchers will use this information to determine how AV-1 affects the volunteers’ ability to recover from dengue compared to placebo and to determine the dosages at which AV-1 may be effective.

    If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and efficacy against dengue virus. For more information about the study, visit ClinicalTrials.gov and search the identifier NCT05048875.

    NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website. 

    About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH…Turning Discovery Into Health®

    ###

    MIL OSI USA News –